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ABSTRACT 
 
 
 Cancer and vascular disease are the two most predominant causes of mortality in 
the United States. Potential regulatory mechanisms for these two diseases have consumed 
research interests. Tetraspanins are cell surface proteins that organize the cell membrane. 
Cellular membrane organization is a prerequisite for cellular signaling to occur. 
Deregulation of cellular signaling often precedes the formation of cancer or vascular 
disease phenotypes. This insinuates the necessity to understand how tetraspanins 
contribute to membrane organization and subsequent downstream signaling. This work 
examines tetraspanin CD9 contributions in a model of cancer cell invasion and vascular 
cell contraction. The findings presented here demonstrate that CD9 expression promotes 
human fibrosarcoma cell invasion by upregulating matrixmetalloproteinase-9 expression. 
These effects were dependent upon an extracellular region of CD9 and involved the 
presence and activity of the epidermal growth factor receptor. In the vascular cell model, 
CD9 elicited the actin arrangement and contraction of human aortic smooth muscle cells 
in a RhoA dependent manner. Taken together these provide insight on how tetraspanins 
regulate diverse cellular phenotypes.  
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PREFACE 
 
 
 Sixth man \ˈsiksth ˈman\ noun. Basketball. 1. a player who is not a starter but 
comes off the bench much more often than other reserves 2. the first player to be 
substituted in a game 3. a player that plays minutes equal to or exceeding some of the 
starters and posts similar statistics. 4. often a player who can play multiple positions.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with permission from http://en.wikipedia.org/wiki/Sixth_man 
 vii 
TABLE OF CONTENTS 
 
CHAPTER 1. TETRASPANINS ......................................................................................1 
The Importance of Membrane Organization ...................................................................1 
Tetraspanin Features and History ....................................................................................1 
Co-conspirators and Resulting Phenotypes .....................................................................4 
Tetraspanin CD9 ..............................................................................................................5 
Rationale of Dissertation .................................................................................................6 
CHAPTER 2. TETRASPANIN CD9 PROMOTES THE INVASIVE 
PHENOTYPE OF HUMAN FIBROSARCOMA CELLS VIA 
UPREGULATION OF MATRIX METALLOPROTEINASE-9 ..................................7 
Introduction ......................................................................................................................7 
Rationale ..........................................................................................................................8 
Materials and Methods .....................................................................................................9 
Reagents and Antibodies ..............................................................................................9 
Cell Culture ..................................................................................................................9 
Expression of CD9 in HT1080 Cells ...........................................................................9 
Experimental Design ..................................................................................................10 
RNA Extraction and qRT PCR Analysis ...................................................................10 
Gelatin Zymography ..................................................................................................10 
Flow Cytometry .........................................................................................................11 
Matrigel Invasion Assay ............................................................................................11 
MMP-1 and MMP-9 ELISAs .....................................................................................12 
Knockdown of MMP-9 in HT1080 Cells ..................................................................12 
Statistical Analysis .....................................................................................................12 
Results ............................................................................................................................13 
CD9 Overexpression in HT1080 Cells Did Not Alter the Expression of Other 
Tetraspanin Family Members ....................................................................................13 
CD9-HT1080 Cells Have Increased Cell Invasion and MMP-9 Production and 
Release .......................................................................................................................16 
Increased CD9-HT1080 Cell Invasion Is a Consequence of Increased MMP-9 .......19 
CD9 Second Extracellular Loop Contributes to Increases in MMP-9 Expression ....21 
CHAPTER 3. PRO-MMP-9 UPREGULATION IN HT1080 CELLS 
EXPRESSING CD9 IS REGULATED BY EPIDERMAL GROWTH FACTOR 
RECEPTOR .....................................................................................................................24 
Rationale ........................................................................................................................24 
Materials and Methods ...................................................................................................24 
Reagents and Antibodies ............................................................................................24 
Western Blot ..............................................................................................................24 
Receptor Tyrosine Kinase Inhibitor Treatment .........................................................25 
Knockdown of EGFR in HT1080 Cells .....................................................................25 
RNA Extraction and qRT-PCR Analysis ...................................................................26 
Statistical Analysis .....................................................................................................26 
 viii 
Results ............................................................................................................................26 
Inhibiting EGFR Signaling Decreases Pro-MMP-9 Release from CD9-HT1080 
Cells ...........................................................................................................................26 
Knockdown of EGFR in CD9-HT1080 Cells Attenuates the Release of Pro-
MMP-9 and Subsequent Cell Invasion ......................................................................26 
CHAPTER 4. CD9 CONTRIBUTIONS TO CANCER CELL BIOLOGY ...............31 
CHAPTER 5. TETRASPANIN CD9 REGULATES CELL CONTRACTION 
AND ACTIN ARRANGEMENT IN HUMAN AORTIC SMOOTH MUSCLE 
CELLS VIA RHOA .........................................................................................................36 
Introduction ....................................................................................................................36 
Rationale ........................................................................................................................36 
Materials and Methods ...................................................................................................37 
Reagents and Antibodies ............................................................................................37 
Cell Culture ................................................................................................................37 
Knockdown of CD9 in HAOSMC Cells ....................................................................37 
RNA Extraction and qRT-PCR Analysis ...................................................................38 
Knockdown of RhoA in HAOSMCs .........................................................................38 
Measurement of the Area of Crystal Violet Stained Cells .........................................38 
Proliferation Assay .....................................................................................................39 
Immunofluorescent Staining of F-actin .....................................................................39 
Detection of Total and GTP-Bound RhoA ................................................................39 
Collagen Gel Contraction Assay ................................................................................40 
Statistical Analysis .....................................................................................................40 
Results ............................................................................................................................40 
CD9 Deficiency Results in Altered Cell Morphology, Proliferation, and SMC 
Marker Expression .....................................................................................................40 
CD9 Deficient HAOSMC Have Altered Actin Arrangement and Decreased 
Contractile Capabilities because of RhoA-Mediated Pathways ................................42 
Activation of RhoA Restores the CD9 shRNA HAOSMC Phenotype ......................45 
Deficiency of Active RhoA or Loss of Total RhoA Mimics the CD9 shRNA 
HAOSMC Phenotype .................................................................................................45 
CD9 Contributions to Vascular Cell Biology ................................................................45 
CHAPTER 6. INSIGHTS INTO CD9 FUNCTION FROM THESE TWO 
MODELS ..........................................................................................................................51 
CHAPTER 7. FUTURE DIRECTIONS ........................................................................54 
LIST OF REFERENCES ................................................................................................55 
APPENDIX A. QRT-PCR PRIMERS ...........................................................................72 
APPENDIX B. SUPPLEMENTARY FIGURES FROM CHAPTERS 5 AND 6 .......75 
VITA..................................................................................................................................77 
 ix 
LIST OF FIGURES 
 
Figure 1-1. Proposed full-length structure of tetraspanin CD9. ........................................2 
Figure 2-1. Overexpression of CD9 in HT1080 cells does not alter the expression of 
other tetraspanins. ........................................................................................14 
Figure 2-2. CD9-HT1080 cells have stable mRNA expression of integrins though α2 
and β1 are reduced at the cell surface. .........................................................15 
Figure 2-3. The invasive phenotype of HT1080 cells is increased upon CD9 
overexpression..............................................................................................17 
Figure 2-4. MMP-9 expression and release are greatly enhanced in CD9-HT1080 
cells. .............................................................................................................18 
Figure 2-5. Silencing MMP-9 in CD9-HT1080 cells is sufficient to suppress the 
invasive phenotype. ......................................................................................20 
Figure 2-6. Characterization of the second extracellular loop (EC2) deletion mutant 
of CD9 in HT1080 cells. ..............................................................................22 
Figure 2-7. An increase in MMP-9 expression and release and subsequent cell 
invasion requires the second extracellular loop (EC2) of CD9....................23 
Figure 3-1. CD9-HT1080 cells release less pro-MMP-9 after treatment with a broad 
spectrum receptor tyrosine kinase inhibitor sunitinib. .................................27 
Figure 3-2. Epidermal growth factor receptor tyrosine kinase inhibitors reduce the 
expression of pro-MMP-9 and inhibit CD9-HT1080 cell invasion. ............28 
Figure 3-3. Knockdown of EGFR results in decreased pro-MMP-9 expression and 
release without affecting the expression or localization of CD9. ................30 
Figure 5-1. Knockdown of tetraspanin CD9 in human aortic smooth muscle cells 
(HAOSMCs) does not affect CD81 or CD151 cell-surface expression. ......41 
Figure 5-2. CD9 deficient HAOSMCs have an altered cell morphology, decreased 
cell size and proliferation, and an increased level of calponin mRNA. .......43 
Figure 5-3. HAOSMCs lacking CD9 display altered actin arrangement and a 
decrease in active RhoA and collagen gel contraction.................................44 
Figure 5-4. Activation of RhoA restores the contractile capabilities of CD9 shRNA 
HAOSMC and partially restores actin arrangement. ...................................46 
Figure 5-5. Suppression of active RhoA or knockdown of total RhoA in HAOSMC 
mimics the phenotype of CD9 shRNA HAOSMC. .....................................47 
 x 
Figure 6-1. The proposed CD9 signaling pathway derived from both model systems. ..53 
Figure B-1. Expression of microRNAs between Ctr and CD9 shRNA HAOSMC. ........75 
Figure B-2. The expression of integrin α5 and β1 subunits on the cell surface of 
naïve HAOSMC. ..........................................................................................75 
Figure B-3. Inhibition of pro-MMP-9 gelatinolytic activity by LY294002, U0126, 
and PD98059. ...............................................................................................76 
 
  
 xi 
LIST OF ABBREVIATIONS 
 
 
BrdU Bromodeoxyuridine 
BSA Bovine Serum Albumin 
CD Cluster of Differentiation 
cDNA Copy Deoxyribonucleic Acid 
CHO Chinese Hamster Ovary 
CN03 RhoA Activator 
CT Cycle Threshold 
CT04 RhoA Inhibitor (C3 Transferase) 
Ctr Scrambled Control 
DAR Donkey Anti-Rabbit 
DMEM Dulbecco’s Modified Eagle’s Medium 
EC1 Extracellular Loop 1 
EC2 Extracellular Loop2 
ECM Extracellular Matrix 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
ELISA Enzyme-Linked Immunosorbent Assay 
ERK Extracellular Signal-Regulated Kinase 
ERM Ezrin-Radixin-Moesin 
FAK Focal Adhesion Kinase 
FBS Fetal Bovine Serum 
FITC Fluorescein Isothiocyanate 
FN Fibronectin 
G418 Geneticin 
GAM Goat Anti-Mouse 
GAR Goat Anti-Rabbit 
GS Goat Serum 
HAOSMC Human Aortic Smooth Muscle Cell 
HEK293 Human Embryonic Kidney Cells 
HRP Horseradish Peroxidase 
HT1080 Human Fibrosarcoma 
Ig Immunoglobulin 
IL Interleukin 
mAb Monoclonal Antibody 
MAPK Mitogen-Activated Protein Kinase 
MMP Matrix Metalloproteinase 
mRNA Messenger RNA 
NSCLC Non-Small Cell Lung Cancer 
PBS Phosphate Buffered Saline 
PI3-K Phosphatidylinositol-3 Kinase 
PKC Protein Kinase C 
PSG Pregnancy Specific Glycoprotein 
PVDF Polyvinylidene fluoride 
 xii 
qRT-PCR Quantitative Real-Time Polymerase Chain Reaction 
SDS Sodium Dodecyl Sulfate 
shRNA Short Hairpin Ribonucleic Acid 
siRNA Small Interfering Ribonucleic Acid 
SmBM Smooth Muscle Basal Medium 
SMC Smooth Muscle Cell 
TBST Tris Buffered Saline with Tween-20 
TGFα Transforming Growth Factor α 
TIMP Tissue Inhibitor of Metalloproteinase 
TM Transmembrane 
UTHSC University of Tennessee Health Science Center 
 
 1 
CHAPTER 1.    TETRASPANINS 
 
 
The Importance of Membrane Organization 
 
 The elaborately regulated process of cellular signaling depends upon membrane 
organization. Transmembrane proteins form multimolecular complexes to relay 
information from the extracellular environment into the cell. Deregulation of cellular 
signaling precedes numerous pathologic events; therefore, thorough understanding of 
membrane organization and its effects is necessary. Of the countless proteins that 
regulate membrane organization, tetraspanins are a relatively new member with alluring 
contributions. This dissertation focuses specifically on the functions of one tetraspanin, 
CD9, in two model systems. The material presented here details how CD9 influences 
cancer and vascular cell phenotypes by assuming the position of a sixth man. This 
comparison personifies the incredible auxiliary role CD9 plays in the regulation of 
cellular phenotypes.  
 
 
Tetraspanin Features and History 
 
 Tetraspanins are a group of 32 distinct mammalian proteins consisting of four 
transmembrane domains. These hydrophobic domains traverse the cell membrane 
resulting in intracellular amino- and carboxy- termini (Figure 1-1). These termini are on 
average 9 to 40 amino acids in length, as determined by comparison of tetraspanin family 
members [1]. Extracellularly, tetraspanins feature two loops of varying size. The first 
extracellular loop (EC1) between the first and second transmembrane domain is 
approximately 22 amino acids in length. The second, much larger, extracellular loop 
(EC2) between the third and fourth transmembrane domain contains 69 to132 amino 
acids and is subdivided into constant and variable regions [2]. The intracellular loop 
located between EC1 and EC2 is a mere 4 amino acids in length [1]. All tetraspanins 
exhibit full conservation of a cysteine-cysteine-glycine amino acid motif and two further 
downstream cysteines in their EC2. This feature distinguishes them from other four 
transmembrane proteins and contributes to the formation of disulfide bonds in the EC2 
variable region. The resulting three dimensional conformation of the EC2 is unique for 
each tetraspanin, and has been utilized to generate highly specific and functional 
monoclonal antibodies (mAbs). Transmembrane proteins are inherently difficult to purify 
and stabilize for crystallography analysis. Consequently, little is known about the full-
length structural features of tetraspanins. Crystallographic studies have been conducted 
only on a homodimerized EC2 of CD81 [3, 4]. These studies provided novel insight into 
the subdomain patterns of CD81 EC2; however, the structure of other tetraspanins to date 
is entirely speculative.  
 
 Tetraspanins were discovered in the 1980s. The first member was discovered 
using the mAb BA-2 on the leukemic cell line NALM-6 [5]. This antigen was termed p24 
antigen as an allusion to its molecular weight of 24 kilodaltons [5]. p24 was found to be 
highly expressed on the cell surface of a variety of cells using different, specific mAbs  
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Figure 1-1. Proposed full-length structure of tetraspanin CD9. 
 
 
and immunofluorescent assays [6-9]. The p24 nomenclature was changed to cluster of 
differentiation 9 (CD9) in 1984 at the First International Workshop on Leukocyte 
Differentiation Antigens [10].The Jennings’ laboratory were the first to report the 
molecular cloning and sequencing of full-length cDNA for p24/CD9 in 1991 [11].The 
gene encoding CD9 is located on chromosome 12p and consists of eight exons spanning 
an approximately 20kB region of the human genome. Transcription generates a 1.4 Kb 
mRNA that translates to a protein of 228 amino acids with a calculated molecular weight 
of 24 kDa [11]. Figure 1-1 details the predicted structure of full-length CD9 within the 
cell membrane. These discoveries initiated interest in tetraspanins as a novel cell-surface 
marker. 
 
 After decades of work, tetraspanins were found to be ubiquitously expressed in 
the majority of mammalian cells and tissues, yet their function was somewhat elusive. 
Cell surface proteins that participate in cellular signaling largely operate by a receptor-
ligand interaction. Tetraspanins are unique in that only two members of the entire family, 
CD9 and CD81, exhibit some interaction with ligands. CD9 serves as a receptor for 
pregnancy-specific glycoprotein 17 (PSG17) [12]. PSGs are a group of soluble proteins 
secreted by the placenta to regulate cytokine production during pregnancy [13]. Binding 
of PSG17 to CD9 on macrophages induced the secretion of anti-inflammatory cytokines 
IL-10, IL-6, PGE2, and TGF-β1, and was blocked by PKC inhibition [14]. The 
interaction between CD9 and PSG17 was fascinating and may have potentially served as 
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a paradigm for how CD9 functions. However, the benefits or consequences of this 
interaction are not understood. There has not been any further exploration of this 
phenomenon in mouse models, and PSG17 is not expressed in humans. In another 
example, the hepatitis C virus envelope glycoprotein E2 bound to CD81 as determined by 
intensive studies involving amino acid mutations, peptide mapping, and monoclonal 
antibody treatments [15]. It was concluded that E2 binds the EC2 of CD81 to facilitate 
viral entry into cells [16, 17]. Although evidence for E2 binding CD81 is very 
convincing, viral binding and entry into cells is multifaceted; therefore, the relevance of 
this interaction is not entirely clear. Accordingly, the idea that tetraspanins function as 
cell surface receptors aside from these two examples has not been widely pursued. 
 
 Despite the blatant scarcity of ligand interactions, there is plenty of evidence that 
suggest tetraspanins regulate multiple essential cellular events including proliferation, 
migration, and metastasis. Less than half of the 32 tetraspanins have been adequately 
scrutinized for their contributions to these processes. Genetic analysis in mice has 
revealed the EC2 and their ability to form complexes with other membrane proteins to be 
fundamental for tetraspanin function [18]. Membrane partner proteins for tetraspanins 
were found to include integrins, Ig superfamily proteins, transmembrane receptors, and 
signaling enzymes [19]. These interactions were initially determined using cell lysis 
detergents that fail to completely solubilize tetraspanins followed by co-
immunoprecipitation experiments [20]. The use of low stringency detergents (e.g. 1% 
Brij 99 or CHAPS) led to the downstream analysis of rather large complexes, which 
resulted in a lack of conclusive evidence for direct interactions. Consequently, tetraspanin 
interactions with other membrane proteins are now more scrupulously considered to be 
primary, secondary, or tertiary. 
 
 Primary interactions are formed between tetraspanins and non-tetraspanin partners 
[21]. These interactions demonstrate high stoichiometry, are detected under stringent 
lysis buffer conditions (e.g. 1% Triton X-100 or 1% NP-40), and retain the ability to be 
stabilized by covalent crosslinking [20]. These stipulations would appear to limit the 
number and complexity of primary tetraspanin interactions. However, these interactions 
are grossly convoluted by the fact that they may differ depending on cell type and may 
associate at different regions of the tetraspanin [21]. For example, CD81 associates with 
the Ig superfamily protein CD19 in B cells [22], but associates with CD4 and CD8 in T 
cells [23]. Additionally, CD81 associates with CD19 extracellularly [24, 25] and with 
EWI-2 intracellularly [26, 27]. Hence, tetraspanin primary interactions are direct but 
diverse and only begin to confound tetraspanin association with other partner proteins 
 
 Secondary and tertiary tetraspanin interactions are defined by their existence in 
either mild (e.g. 1% Brij 96 or 1% Brij 97) or low stringency detergents (e.g. 1% 
CHAPS), respectively [21]. Secondary interactions include tetraspanin-tetraspanin 
associations into homo- or hetero-multimers [28]. These interactions are strengthened by 
the presence of divalent cations and are dependent upon palmitoylation of 
juxtamembrane cysteines as determined by site directed mutagenesis [29, 30]. The 
addition of palmitic acid strengthens tetraspanin association with the hydrophobic cell 
membrane and ancillary protein interactions [30]. CD9 association with CD81 is 
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abolished upon the mutation of juxtamembrane cysteines in CD9 thus providing strong 
evidence for the importance of palmitoylation in the formation of tetraspanin complexes 
[30]. Secondary interactions depend on more than the sole presence of tetraspanins and 
partner proteins on the cell surface, and, unlike primary interactions, are not highly 
stoichiometric [21]. Tertiary interactions simply represent additional proteins associated 
with tetraspanins under low stringency buffer conditions. Taken together, primary, 
secondary, and tertiary interactions result in the formation of membrane microdomains 
called tetraspanin webs [31] or tetraspanin-enriched microdomains [32]. The formation of 
these complexes illustrates how tetraspanins may regulate cellular phenotypes. As a 
consequence of these interactions it becomes difficult to pinpoint the exact contributions 
of a particular tetraspanin.  
 
 
Co-conspirators and Resulting Phenotypes 
 
 Integrins are the most characterized and essential cell surface partner to 
tetraspanins. Integrins are heterodimers of one α and one β subunit that primarily function 
to bind cells to extracellular matrix (ECM). There are 18 different α and 8 different β 
subunits. The majority of the α and β subunits are followed by Arabic numerals for 
distinction. Of the greater than 40,000 potential heterodimer combinations, only 24 have 
been reported in mammalian cells. These 24 distinct combinations are widely expressed 
and contribute to integrin specificity for certain ECM ligands [33]. Upon binding ECM, 
integrins may relay messages to the cell to promote or inhibit several cellular activities 
including apoptosis, adhesion, and migration [34, 35]. It is not a coincidence that 
processes attributed to integrin function are similar to those attributed to tetraspanins. 
Numerous reports have determined that tetraspanins function primarily by their 
association and ability to manipulate integrin activities. 
 
 Specific complexes of tetraspanins with β1 integrins modulate integrin-mediated 
cellular phenotypes [36-38]. The tetraspanin CD151 EC2 primary interaction with the 
integrin α3β1 is arguably the most characterized tetraspanin-integrin interaction [39, 40]. 
CD151 and α3β1 associate in a high stoichiometric ratio approaching 1:1 and are able to 
be covalently crosslinked [41-43]. Treatment with monoclonal anti-CD151 inhibitory 
antibodies resulted in the increased adhesion and decreased migration and invasion when 
plated on laminin, an α3β1 integrin ligand [36, 44]. These effects were not apparent on 
fibronectin, a ligand for α5β1 [36, 44]. The same outcomes were observed using 
monoclonal anti-α3 antibodies [44]. Notably, α3β1expression in the absence of CD151 
has not been observed [20]. It has been hypothesized that CD151 may be required for 
α3β1 cell surface expression due to their association in early biogenesis within the 
endoplasmic reticulum [39, 43]. This interaction may depend on the tyrosine (Y)-based 
sorting motif found at the C-terminus of CD151 [45]. This YXXϕ motif, where X is any 
amino acid and ϕ is a hydrophobic amino acid, is also found in two other tetraspanins, 
CD63 and CD82, and is required for endosomal and lysosomal recycling pathways [46, 
47]. CD151 associates with both CD9 and CD81 [48, 49]. As a result, CD151 association 
with α3β1 links CD9 and CD81 to α3β1 [50]. The loss of CD151 expression dissolved 
these interactions and blocked α3β1-dependent cell motility [50]. Likewise, knockdown 
 5 
of CD9 or CD81, or treatment with Gö6976, a PKC inhibitor, inhibited cell motility [50]. 
This indicates that CD9 and CD81 promote α3β1-dependent cell motility through a 
integrin-tetraspanin-PKC dependent pathway [50]. The interaction between CD151 and 
α3β1 and the consequences of this interaction provides insight for how tetraspanins and 
integrins may work collectively to either promote or inhibit cellular phenotypes. 
 
 Ig superfamily proteins also associate with tetraspanins. EWI-2 and EWI-F appear 
to be the most significant Ig superfamily partners. Both proteins contain a glutamic acid-
tryptophan-isoleucine motif not apparent in other Ig superfamily proteins [27]. EWI-2 
and EWI-F form primary interactions with CD9 and CD81 independently as suggested by 
EWI-2/-F-CD9 and EWI-2/-F-CD81 high stoichiometry and cross linking experiments 
[27]. These associations may link CD9 and CD81 to ezrin-radixin-moesin (ERM) 
proteins as EWI-2/-F co-localized and co-immunoprecipitated with ERM proteins [51]. 
EWI-2 siRNA treatment resulted in increased cell migration and polarity and increased 
the phosphorylation of ERM [51]. CD9 and CD81 may negatively regulate cell migration 
by helping link EWI-2 to ERM proteins [51]. The associations with integrins and Ig 
superfamily proteins provide a mechanism for how tetraspanins regulate cellular 
phenotypes.  
 
 
Tetraspanin CD9 
 
 Conclusive evidence of tetraspanin function was predominantly achieved in one 
of three ways: 1) knockout mice, 2) functional antibody analyses, or 3) knockdown or 
overexpression experiments. The first tetraspanin knockout mice generated were for 
tetraspanin CD9 [52-54]. These mice were viable and only suffered from significantly 
reduced female fertility [52-54]. The lack in fertility was attributed to the inability of 
sperm to fuse with CD9 deficient ova [52]. The unexceptional phenotype of CD9-/- mice 
was not entirely without merit. It was discovered that CD81-/- mice demonstrated 
similarly diminished female fertility [55]. Sequence alignment studies of CD9 and CD81 
provided evidence for potentially overlapping functions between these two proteins. This 
gave rise to the hypothesis that some tetraspanins may compensate in the absence of 
others.  
 
 Sequence alignment provides some cause to separately consider mouse and 
human CD9 findings. Although the two are 89% identical, 23% of their differences lie in 
the EC2 of CD9 [56]. Further dissection of EC2 into constant and variable regions 
increases the percentage of difference between mouse and human CD9 to 32% in the 
variable region. This marginal difference is intensified by two details. First, the sperm-
egg fusion properties attributed to mouse CD9 were mapped to residues SFQ (173-175) 
[57] which align with the human residues TFT (175-177). The non-conservative 
glutamine to threonine switch in the third position is distinguishing; however, the 
expression of human CD9 in CD9-/- mouse oocytes repaired sperm-egg fusion to 90% 
suggesting the switch is trivial and not associated with a phenotypic change. Second, the 
association of CD9 to heparin-binding EGF-like growth factor (HB-EGF) was dependent 
upon three human CD9 residues G158, V159, and T175 [58]. The expression of human 
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and monkey CD9 upregulated the binding of diphtheria toxin to cells as a consequence of 
CD9-pro-HB-EGF association. Mouse CD9 expression did not have the same result. The 
corresponding required residues in mouse CD9 are P156, L157, and S173. The valine to 
leucine and threonine to serine are conservative changes that most likely do not 
contribute to differences in mouse and human CD9. However, the glycine to proline 
switch is the most pronounced, non-conservative difference. This proline is absent when 
human CD9 restores the sperm-egg fusion properties in CD9-/- mice, thus the fusion 
abilities of CD9 are likely influenced independently of this proline residue. Nevertheless, 
the proline at position 156 in mouse CD9 plausibly distinguishes the functions of mouse 
and human CD9 in some phenotypes. 
 
 
Rationale of Dissertation 
 
 As a result of the previous findings regarding tetraspanins, this body of work will 
focus specifically on the functions of one tetraspanin, CD9, in two well-defined human 
model systems. This dissertation is divided into two sections. The first section, Chapters 
2 through 4, details the function of CD9 in a cancer cell biology model of invasion. The 
second section, Chapter 5, details the function of CD9 in a vascular biology model of 
contraction. Chapter 6 is discussion of how the findings in both model systems may 
overlap. 
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CHAPTER 2.    TETRASPANIN CD9 PROMOTES THE INVASIVE 
PHENOTYPE OF HUMAN FIBROSARCOMA CELLS VIA UPREGULATION 
OF MATRIX METALLOPROTEINASE-9* 
 
 
Introduction 
 
 Tetraspanins’ role in proliferation, migration, and invasion led to their implication 
in the pathogenesis of tumor cell metastasis. The effects tetraspanins have on multiple 
cell phenotypes provide an assortment of possibilities for them to regulate cancer cell 
metastasis. Anti-CD151 blocking antibodies repressed metastasis solely by inhibiting cell 
motility without affecting proliferation or EMC degradation [59]. Contrarily, expression 
of tetraspanin CO-029 increased intrahepatic metastasis without affecting tumor growth 
at the primary site [60]. This indicates that CO-029 expression affects invasion without 
affecting proliferation. Multiple other combinations of tetraspanin regulation quickly 
emerged and each tetraspanin was rapidly labeled as either a tumor suppressor or 
promoter based on study findings. Unfortunately, this simplification neglected to recall 
the diverse expression of tetraspanins on mammalian cells, their cell-type dependent 
interactions, and their hierarchy of membrane organization. As a result, some tetraspanin 
labels were muddled as they were found to be suppressors in one cell line and promoters 
in another. Tetraspanin function is now carefully considered in the context of the cell 
line(s) or model used to demonstrate the results. 
 
 Two tetraspanins – CD9 and CD151 – make the most prominent contributions to 
cancer cell biology [61, 62]. There is a considerable amount of evidence indicating 
CD151 promotes metastasis and no evidence at the present indicating it suppresses 
metastasis [61, 63]. CD151 overexpression is observed in many tumors including brain 
[64], breast [65], colon [66], lung [67], pancreas [68], and prostate [69]. Its 
overexpression is associated with a poor prognosis [63]. CD151 is so tightly linked with 
metastasis that it was found to be a better prognosis predictor than histologic grading in 
primary prostate cancers [69]. CD9 on the other hand is noticeably labeled as a tumor 
suppressor [70-72]. Nonetheless, there is an increased amount of evidence that tips the 
balance and supports a role for CD9 in cancer metastasis [73-75]. In vivo studies 
suggested that increased CD9 expression correlated with advanced gastric cancer and a 
poor prognosis [76, 77]. Another study conducted on prostatic carcinoma progression 
noted a significant increase in CD9 expression in primary, metastasizing adenocarcinoma 
compared to advanced, non-metastasizing adenocarcinomas [78]. Strong CD9 expression 
in histologic analysis of metastasizing cancers implies its significance in the metastatic 
capabilities of cancer cells. 
 
 Tetraspanins may specifically regulate the invasive properties of cancer cells by 
controlling the expression and release of matrix metalloproteinases (MMPs) and tissue 
                                                 
 
* Adapted with permission from Public Library of Science. Herr MJ, Kotha J, Hagedorn N, Smith B, 
Jennings LK (2013) Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via 
upregulation of matrix metalloproteinase-9. PLoS One 8: e67766. 
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inhibitors of metalloproteinases (TIMPs). MMPs are a family of 23 mammalian zinc-
dependent endopeptidases that facilitate the degradation of specific components of the 
ECM preceding cellular invasion [79-81]. The majority of MMPs are secreted as soluble, 
inactive proteins that have regulatory domains called pro-domains [80]. These pro-
domains may be cleaved off by other proteases in a series of regulated steps that result in 
their activation [82]. Other MMPs are membrane bound and may by regulated by their 
association with other membrane proteins [82]. There are four distinct TIMPs that 
endogenously regulate MMPs with varying specificity [79, 83]. When first discovered as 
promoters of invasion, MMPs quickly became prominent pharmacologic targets to 
alleviate metastasis. Eventually, broad spectrum inhibitors were developed to regulate 
MMP activity in vivo. However, these inhibitors demonstrated lack of clinical efficacy 
and studies were discontinued primarily because pharmacological intervention after 
metastasis had occurred was futile [84-86]. Interest in MMP research has since shifted to 
finding other ways to regulate their expression, release, and activity prior to metastasis. 
 
 The regulation of MMP and TIMP activity by tetraspanins is a well-documented 
event. Expression of CD63 [87] and CD151 [88] are involved in the downregulation of 
MT1-MMP activity either by proteolysis or association, respectively. TIMP1 cell surface 
expression depends on CD63 expression and their association in human breast epithelial 
cells [89]. Furthermore, double deficiency of CD9 and CD81 resulted in increased 
amounts of MMP-2 and MMP-9 in a mouse macrophage cell line [90], and CD151 
activated pro-MMP-7 in osteoarthritic chondrocytes [91]. CD151 expression and 
clustering led to the activation of α3β1 and α6β1 integrins which activated the 
FAK/Src/p38MAPK pathway [92]. This triggered cJun to bind AP-1 and increase MMP-
9 expression in CD151-deficient human melanoma cells [92]. Multiple cancerous cell 
lines expressing CD9 either endogenously or exogenously exhibited diminished cell 
motility [70, 93, 94]; however, there is notable ambiguity on the effect CD9 expression 
may have on the invasive cell phenotype by regulating MMP and TIMP production. In 
keratinocytes, CD9 and MMP-9 expression were indirectly related [94]. Similarly, CD9-
null mice experience significant wound healing delay due to increased MMP-9 
expression in an in vivo wound healing model [95]. In human melanoma cells CD9 
expression induced the expression of MMP-2 and inhibited MMP-9 [96]. In contrast, 
CD9 expression in a small cell lung cancer cell line suppressed MMP-2 expression [97]. 
Thorough analysis of tetraspanin web components, MMP expression, and a clear 
distinction between migration and invasion in a cell-specific context is lacking. Thus, 
CD9-specific effects on MMP expression and cellular invasion is somewhat ambiguous. 
 
 
Rationale 
 
 Human fibrosarcoma (HT1080) cells are a highly invasive cell line commonly 
used as an in vitro model of metastasis [98-101]. These cells endogenously express low 
levels of the tetraspanin CD9. It was explored whether or not CD9 overexpression had 
any phenotypic effect on HT1080 cell invasion to better understand the contribution of 
CD9 to metastasis. 
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Materials and Methods 
 
 
Reagents and Antibodies 
 
 Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), goat 
serum (GS), penicillin-streptomycin, Geneticin (G418), full-length human plasma 
fibronectin (FN), and phosphate buffered saline (PBS; pH 7.4) were purchased from 
Gibco (Grand Island, NY). Antibodies to anti-human CD9 EC2 (mAb7) were generated 
prior to this work and was previously described [102]. A rabbit polyclonal antibody 
specific for the first extracellular loop of CD9 (Rap2) was also previously generated and 
described [103]. Anti-human α2 antibody (mAb1950Z) was purchased from Millipore 
(Temecula, CA). Anti-human CD81 (sc-7637), α4 (sc-6589), α5 (sc-13547), α6 (sc-
13542), and β1 (sc-53711) were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA), anti-human CD63 (#566019) and anti-human CD151 (#556056) were purchased 
from BD Biosciences (Durham, NC). Polybrene, puromycin, and anti-human β-tubulin 
(T2200), IgG, and Fluorescein Isothiocyanate (FITC)-conjugated anti-mouse (F2012) 
antibodies were purchased from Sigma Aldrich (St. Louis, MO). Matrigel from 
Engelbreth-Holm-Swarm mouse tumor (#354234) and 8.0 μm pore cell culture inserts 
(353097) were purchased from BD Biosciences (Bedford, MA). Lipofectamine 2000 
transfection reagent was purchased from Invitrogen (Carlsbad, CA). 
 
 
Cell Culture 
 
 Human fibrosarcoma (HT1080) cells were purchased from American Type 
Culture Collection (Manassas, VA) were cultured in DMEM supplemented with 10% 
FBS, 1% penicillin-streptomycin in a humidified, 5% CO2, and 37°C incubator. Cells 
were regularly passaged every 72-96 hours and were used between passages 2 and 5 after 
bringing out of liquid nitrogen. 
 
 
Expression of CD9 in HT1080 Cells 
 
 Wild type HT1080 cells were transfected by electroporation with either the empty 
pRC/CMV plasmid (Mock), the pRC/CMV plasmid containing full-length human CD9 
cDNA insert (CD9), or the pRC/CMV plasmid containing CD9 cDNA insert without the 
nucleotides coding for the second extracellular loop amino acids 173-192 (Δ6). To obtain 
stable transfectants, transfected cell populations were selected by the addition of media 
containing Geneticin (G418, 0.75 mg/ml). All cells were cultured in a humidified, 5% 
CO2, 37°C incubator. 
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Experimental Design 
 
 For each experiment, FN was diluted to 10μg/ml in PBS and 2 ml was added to 
each well of 6-well cell culture dishes and allowed to incubate at 37°C for 3 hrs. The FN-
PBS solution was then aspirated and any residual solution was washed with PBS. 
Subconfluent HT1080 cells were harvested, counted, and suspended as 5.0x105 cells/ml 
in serum-free (SF) DMEM. 1.0x106 cells were added to each FN-coated well in a final 
volume of 2 ml of SF DMEM and allowed to incubate for 24 hours before the media was 
collected and the cells were harvested.  
 
 
RNA Extraction and qRT PCR Analysis 
 
 RNA was extracted from cells using the RNeasy minikit (74104, Qiagen, 
Valencia, CA) per the manufacturer’s instructions and eluted in DNase/RNase free water. 
The RNA quantity was estimated using a nanodrop spectrophotometer (Thermo 
Scientific, Rockford, IL) and RNA integrity was assessed using Agilent bioanalyzer 2100 
(Santa Clara, CA). Considerations were taken to use RNA with 260/280 and 260/230 
ratios higher than 1.90 (2.0 or slightly higher being perfect) and a RNA integrity number 
greater than 9.90 (10.0 being completely undegraded). cDNA was made from 1μg of total 
HT1080 RNA with an RNA cDNA synthesis kit from Applied Biosystems (Foster City, 
CA). The resulting cDNA was tested in triplicate by qRT-PCR using TaqMan chemistry 
and probes (Roche, Indianapolis, IN) and a Roche Lightcycler 480 system at the UTHSC 
Molecular Resource Center. Forward and reverse primers were designed using the Roche 
Universal Probe Library Design Software and ordered from Sigma Aldrich (Tables A-1 
and A-2). Primer efficiency was tested on serial dilutions of universal human RNA. 
Primers with an efficiency of greater than 1.80 (2.0 indicating perfect binding even at 
1:1,000 dilution of cDNA) were used in subsequent experiments. Fold changes in mRNA 
expression were calculated from the averaging the resulting cycle threshold (CT) values. 
Average CT values were normalized (subtracted) to Cyclophilin-D housekeeping gene 
(ΔCT). The ΔCT values for the control treated cells were subtracted from the 
experimental treatment values (ΔΔCT). Fold changes in the experimental group relative 
to the control group mRNA were calculated by 2-ΔΔCT. Fold changes greater than 2 or 
less than 0.5 were considered to be meaningful deviation from the control. The fold 
changes from three independent experiments were averaged to determine the mean fold 
change and standard deviation from the mean. 
 
 
Gelatin Zymography 
 
 Cell culture supernatant was harvested from cells plated on 10μg/ml FN for 24 
hours as described above and clarified by a two-step centrifugation at 800xg and 1400xg 
at 4°C. The resulting culture supernatant was mixed with non-reducing sample buffer and 
subjected to electrophoresis on 10% SDS-polyacrylamide gels containing 1 mg/ml final 
concentration of porcine gelatin (Sigma Aldrich). After electrophoresis, SDS was 
removed by washing gels with 2.5% (v/v) Triton X-100 solution. The gels were 
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incubated in digestion buffer (50 mM Tris, 200 mM NaCl, and 10 mM CaCl2) for 14 
hours at 37°C and then fixed in a solution containing 50% ethanol and 10% acetic acid 
for 2 hours at room temperature. The gels were then washed twice in 50% methanol and 
10% acetic acid solution and stained with 0.1% Coomassie brilliant blue R-250 (BioRad, 
Hercules, CA) in 20% methanol and 10% acetic acid solution for 2 hours. The gels were 
destained with a 50% methanol and 10% acetic acid solution, scanned using a Hewlett-
Packard Office Jet Pro 8500 Premier scanner. Gelatinolytic bands were indicated by the 
absence of Coomassie staining. Band intensity was subjected to densitometry analysis 
using NIH Image J software. In the cases where pro-MMP-9 and pro-MMP-2 were 
considered, relative intensity was calculated by dividing the intensity of the MMP-9 band 
by the MMP-2 band, then normalizing the data to the corresponding control treatment 
bands. In the cases where pro-MMP-9 was considered alone, relative intensity was 
calculated by dividing by the pro-MMP-9 band in the experimental treatment lane by the 
band in the control treatment lane. A minimum of three independent experiments were 
performed for quantitation of relative band density. 
 
 
Flow Cytometry 
 
 Cells were harvested, counted, and suspended at 5.0x105 cells/ml in 5% goat 
serum-DMEM (blocking media) and incubated on ice for 45 minutes to block non-
specific binding. All subsequent antibody incubations were performed on ice. Primary 
antibody was added to a final concentration of 5 μg/ml and incubated for 1 hour. 
Unbound primary antibody was removed by washing the cells three times. One wash 
consisted of pelleting the cells (800xg for 5 min), discarding the supernatant, and 
suspending the cell pellet using 1 ml of ice-cold PBS by pipetting. The cells were 
incubated with secondary FITC-conjugated antibody at a final concentration of 5 μg/ml 
in blocking media for 1 hour. The secondary antibody was removed by washing three 
times, and the cells were suspended in room-temperature PBS after the last wash for data 
acquisition. Analysis of the data was performed using a FACS Calibur flow cytometer 
equipped with Cell Quest Pro software (Becton-Dickinson, Bedford, MA). The geometric 
mean fluorescence intensity values were averaged among three or more independent 
experiments. 
 
 
Matrigel Invasion Assay 
 
 Matrigel diluted to 250 μg/ml in matrigel coating buffer (0.01M Tris, 0.7% NaCl, 
pH 8.0, sterile filtered) was added to 8.0 μm pore cell culture inserts and allowed to 
solidify at 37°C for 1 hr. 1.0x105 Mock- and CD9-HT1080 cells were added to separate 
cell culture inserts, and 1% FBS-DMEM was added to the bottom well as a 
chemoattractant. As a control for migration, equal amounts of cells were added to 
uncoated cell culture inserts. As a negative control, cells were added to matrigel-coated 
inserts and serum-free DMEM was added to the bottom well. The 24-well tissue culture 
plates were placed in a humidified, 5% CO2, 37°C incubator. After 20 hours incubation, 
the inside of the tissue culture insert was cleared of cells by scrubbing with a cotton 
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swab. The cells on the bottom of the insert were fixed in ice-cold 100% methanol for 2 
minutes, rinsed twice with PBS, and stained using 0.05% crystal violet for 30 minutes. 
After rinsing off residual crystal violet with PBS, the culture insert membranes were air 
dried, cut out, and mounted onto microscope slides with Permount (Fisher). Cells were 
counted in 10 random fields of view per membrane. Counts from at least three 
independent repeats were averaged to come up with the average number of cells/field of 
view. 
 
 
MMP-1 and MMP-9 ELISAs 
 
 ELISA kits for MMP-1 (ELH-MMP1) and MMP-9 (BMS2016/2) were purchased 
from RayBiotech, Inc (Norcross, GA) and eBioscience (San Diego, CA), respectively. 
Analysis of pro- and active-proteinase expression was performed per the manufacturer’s 
protocol using cleared supernatant from Mock- and CD9-HT1080 cells incubated for 24 
to 48 hours on 10 μg/ml FN-coated cell culture plates in serum-free DMEM. Samples 
were run in duplicate, and results were compared to a curve generated using reconstituted 
protein standards supplied with each kit. The lower limits of detection for MMP-1 and 
MMP-9 were less than 8 pg/ml and 50 pg/ml, respectively. The calculated overall intra-
assay coefficients of variation were less than 10%. 
 
 
Knockdown of MMP-9 in HT1080 Cells 
 
 Small interfering RNA (siRNA) oligomer duplexes targeting MMP-9 were 
ordered from Sigma Aldrich (St. Louis, MO). Three different MMP-9 siRNAs were 
initially screened for their effects on tetraspanin, integrin, and MMP expression. One 
siRNA was successful at silencing MMP-9 expression without affecting other 
tetraspanins, integrins, and MMPs pertinent to this study and was chosen for subsequent 
experiments. A non-specific, scrambled siRNA was used as a control. Transfection was 
performed on a subconfluent monolayer of Mock- or CD9-HT1080 cells using 
Lipofectamine 2000 transfection reagent. After 6 hours incubation with siRNA and 
Lipofectamine 2000, the cell monolayer was washed and the cells were incubated with 
complete media. The cells were harvested and used in subsequent experiments 48 hours 
after transfection. 
 
 
Statistical Analysis 
 
 All experiments were repeated at least three independent times and most samples 
were tested in either duplicate or triplicate. Statistical analysis was carried out using 
SPSS software, and graphs were generated using GraphPad Prism 6 software. The bars 
represent the mean, and error bars represent the standard deviation from the mean. An 
independent samples t-test or Mann-Whitney U Test was used to compare two means of 
normally distributed or non-normally distributed samples, respectively. Analysis of 
Variance (ANOVA) was used to compare three means of normally distributed 
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homogenous data. Tukey’s HSD post-hoc analysis was conducted to determine any 
difference among the groups. Welch’s ANOVA was used for three sample means with 
non-normally distributed data, and Dunnet’s T3 post-hoc analysis was used to determine 
any difference among these means. Each test was run at a 95% confidence level and P-
values less than 0.05 were considered statistically significant. 
 
 
Results 
 
 
CD9 Overexpression in HT1080 Cells Did Not Alter the Expression of Other 
Tetraspanin Family Members 
 
 Human fibrosarcoma (HT1080) cells endogenously expressed low levels of CD9 
on their cell surface as indicated by flow cytometry (Figure 2-1A). A population of CD9-
expressing HT1080 cells was generated by transfecting wild-type HT1080 cells with a 
plasmid containing a full-length human CD9 cDNA insert. Likewise, the same plasmid 
without the CD9 insert was used to generate Mock-HT1080 cells. Stably transfected cell 
colonies were generated by multiple passages of these transfected cells in G418-
containing selection media. CD9 mRNA levels were upregulated approximately 20-fold 
in CD9-HT1080 compared to Mock-HT1080 cells (Figure 2-1B). The mRNA levels of 
other constitutively expressed members of the tetraspanin family – including CD63, 
CD81, and CD151 – were not significantly changed as a result of CD9 expression 
(Figure 2-1C). Flow cytometry was used to further confirm that changes in mRNA 
expression corresponded with the proper trafficking of tetraspanins and their expression 
on the cell surface. Increased CD9 expression may have consequences on the cell surface 
expression of other tetraspanins due to rearrangement of the tetraspanin-enriched 
microdomain. A prominent increase was observed in the expression of CD9 at the cell 
surface of CD9-HT1080 cells relative to the Mock transfected HT1080 cells (Figure  
2-1D). The mean fluorescence intensity was 11.4±2.3 and 538.8±149.1 for Mock- and 
CD9-HT1080 cells, respectively (p<0.001). Exogenous expression of CD9 did not 
significantly affect the cell surface expression of tetraspanins CD63, CD81, or CD151 
(Figure 2-1D). Thus, any phenotypic differences between Mock- and CD9-HT1080 cells 
may be attributed directly to upregulation of CD9 expression.  
 
 Other major regulators of activity within tetraspanin-enriched microdomains 
include integrins [1, 104]. Changes in the mRNA expression of integrin subunits α2, α4, 
α5, α6, and β1 between Mock- and CD9-HT1080 cells were measured using qRT-PCR. 
CD9 expression did not elicit any modifications in integrin subunit mRNA production 
(Figure 2-2A). The cell surface expression of integrin subunits α4, α5, and α6 was 
unaffected by CD9 overexpression as determined by flow cytometric analysis of 
unpermeabilized cells (Figure 2-2B). However, the cell surface expression of α2 and β1 
integrin subunits was lower in CD9 transfectants (Figure 2-2B). CD9-HT1080 α2 
fluorescence intensity values were 1.4 fold less and β1 values were 1.2 fold less than 
Mock-HT1080 values (p<0.001, and p=0.002, respectively). These findings suggest a  
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Figure 2-1. Overexpression of CD9 in HT1080 cells does not alter the expression 
of other tetraspanins. 
(A) The cell surface expression of CD9 on wild-type HT1080 cells was assessed using 
flow cytometric analysis after binding a monoclonal antibody specific for CD9 (mAb7, 
shaded histogram). A non-specific isotype-matched antibody (IgG) was used as a 
negative control (unshaded histogram). (B, C) Total RNA was collected from Mock- and 
CD9-HT1080 cells, reverse transcribed to cDNA, and probed using primers specific for 
integral tetraspanins using qRT-PCR. The fold change in mRNA expression of 
tetraspanins was calculated from resulting cycle threshold values normalized to 
cyclophilin D. (D) Flow cytometry was used to assess the cell surface expression of key 
tetraspanins on the cell surface of Mock- (left panels) and CD9- (right panels) HT1080 
cells **, p<0.001. 
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Figure 2-2. CD9-HT1080 cells have stable mRNA expression of integrins though 
α2 and β1 are reduced at the cell surface. 
(A) The fold change in mRNA expression of integrins was compared between Mock- and 
CD9-HT1080 cells using qRT-PCR. (B) Cell surface expression of the same integrin 
subunits (shaded histograms) was evaluated by flow cytometry. A non-specific isotype-
matched antibody (IgG) was used as a negative control (unshaded histograms). 
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small though statistically significant decrease in the integrin heterodimer α2β1 at the cell 
surface. 
 
 
CD9-HT1080 Cells Have Increased Cell Invasion and MMP-9 Production and 
Release 
 
 Tetraspanins are known to regulate the metastatic phenotype of tumor cells [59, 
60]. A matrigel invasion assay was used to establish any differences in the invasive 
phenotype of HT1080 cells following the expression of CD9. After 20 hours of invasion, 
45% more CD9-HT1080 cells migrated through matrigel-coated cell culture inserts 
compared to Mock-HT1080 cells (p=0.002; Figure 2-3A and 2-3B). This infers that the 
presence of CD9 on the cell surface contributes to an increase in the invasive capabilities 
of HT1080 cells.  
 
 Invasion of cancer cells is tightly regulated by a balance in MMP and TIMP 
production [81, 82], and tetraspanins have previously been demonstrated to regulate 
MMP and TIMP expression in other cell lines [90-92, 105]. CD9 regulation of MMP and 
TIMP expression in HT1080 cells was a conceivable mechanism to augment cellular 
invasion.  qRT-PCR was used to examine if CD9 overexpression had any effect on 
relative MMP or TIMP mRNA levels. The results indicated a 4.1-fold increase in the 
production of MMP-9 mRNA in cells overexpressing CD9 compared to Mock (Figure  
2-4A). A 3.9-fold decrease in the expression of MMP-1 mRNA was also observed. The 
mRNA expression levels of other relevant  MMPs and three TIMPs including MMP-2, 
MMP-3, MMP-7, MMP-8, MMP-14 (MT1-MMP), MMP-16 (MT2-MMP), TIMP-1, 
TIMP-2, and TIMP-3 were unchanged between Mock- and CD9-HT1080 cells (Figure  
2-4A). Upon using multiple different and efficient primers, TIMP-4 mRNA expression 
was not detectable in either Mock- or CD9-HT1080 cells. 
 
 MMP-1 and MMP-9 specific ELISAs were used to establish if the observed 
mRNA changes resulted in changes in soluble proteinase release into the media. MMP-1 
proteinase concentration in the supernatants from CD9-HT1080 cells tended to be less 
than that detected in the Mock cells; however, this change was not statistically significant 
(Figure 2-4B). Consistent with increased MMP-9 mRNA levels, MMP-9 proteinase 
concentration in the supernatant of CD9-HT1080 cells was 3.7 fold higher than Mock-
HT1080 cells (Figure 2-4C). The concentration of MMP-9 was on average much greater 
than the concentration of MMP-1 (Figure 2-4B and 2-4C). There was a very strong 
direct correlation between the levels of CD9 mRNA expression and the proteinase 
concentration of MMP-9 in the CD9-HT1080 cell supernatant after 48 hours (Pearson 
correlation coefficient = +0.973, p=0.027). These findings suggest the possible 
involvement of CD9 expression inducing MMP-9 mRNA synthesis and release into the 
supernatant. 
 
 Variations in the secretion of gelatinase MMP-9 in cell culture supernatants were 
confirmed using a gelatin zymogram. Pro-MMP-9 gelatinolytic band intensity was 
augmented in the cell culture supernatant of CD9-HT1080 cells (Figure 2-4D). 
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Figure 2-3. The invasive phenotype of HT1080 cells is increased upon CD9 
overexpression. 
A matrigel invasion assay was used to assess the invasive properties of Mock- and CD9-
HT1080 cells. Cells were allowed to invade through matrigel and adhere to the bottom of 
a cell culture insert as detailed in the Materials and methods section. (A) A representative 
image of stained cells after 20 hours of invasion though matrigel. (B) Invasion through 
matrigel-coated inserts was compared to cells that invaded through uncoated inserts and 
results shown are normalized to Mock-HT1080 cell invasion *, p<0.05. 
 18 
 
 
Figure 2-4. MMP-9 expression and release are greatly enhanced in CD9-HT1080 
cells. 
(A) Fold changes in MMP and TIMP mRNA expression for Mock- and CD9-HT1080 
cells were calculated from cycle threshold values using qRT-PCR. (B, C) Specific ELISA 
kits were used to measure the concentration (ng/ml) of pro- and active- MMP-1 and 
MMP-9 in the cleared supernatant of Mock- and CD9-HT1080 cells. (D) A representative 
gelatin zymogram of Mock- and CD9- HT1080 cell conditioned media. The absence of 
Coomassie staining at 92 kDa indicates the presence of pro-MMP-9 and at 72 kDa 
represents pro-MMP-2. (E) Quantification of the relative band intensity was calculated by 
densitometry analysis as described in the Materials and methods section *, p<0.05; **, 
p<0.001. 
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The 72 kDa pro-MMP-2 gelatinolytic band was similar in both Mock- and CD9-HT080 
conditioned media and served as a loading internal control. Quantification of  the relative 
density of the enzymatic bands established that pro-MMP-9 secretion was two-fold 
greater in CD9-HT1080 cells compared to Mock cells (Figure 2-4E). The amount of pro-
MMP-2 in the cell supernatant was not significantly different between Mock- and CD9-
HT1080 cells. 
 
 
Increased CD9-HT1080 Cell Invasion Is a Consequence of Increased MMP-9 
 
 Increased MMP-9 mRNA expression and proteinase release into the media was 
possibly responsible for the increased invasive cell phenotype observed in the CD9-
HT1080 cells. To test this hypothesis, short-interfering RNA (siRNA)-mediated silencing 
approach was utilized to transiently knock down MMP-9 expression in CD9-HT1080 
(CD9+MMP9 siRNA). A scrambled control siRNA was transfected into Mock- and 
CD9-HT1080 cells and used as a control (Mock+Ctr siRNA and CD9+Ctr siRNA). Upon 
transfection, there was significantly less MMP-9 mRNA expression in CD9+MMP-9 
siRNA compared to CD9+Ctr siRNA (Figure 2-5A). The mRNA expression levels of 
CD9, CD81, CD151, MMP-1, and MMP-2 were unchanged upon transfection with 
MMP-9 siRNA. Treatment with MMP-9 siRNA in CD9-HT1080 cells resulted in 46% 
decrease MMP-9 proteinase concentration in the conditioned media compared to 
CD9+Ctr siRNA as measured by ELISA (Figure 2-5B). There was no significant 
difference in the MMP-9 concentration of Mock+Ctr siRNA and CD9+MMP9 siRNA 
HT1080 cell conditioned media. These results confirm that silencing of MMP-9 in CD9-
HT1080 cells lowers the expression and release of MMP-9 to that observed in Mock-
HT1080 cells. 
 
 Gelatin zymography analysis of cell supernatants fully supported the qRT-PCR 
and ELISA findings. There was a significant difference in the amount of pro-MMP-9 in 
the cell culture supernatant between the three groups of transiently transfected cells. 
CD9+MMP-9 siRNA gelatin degradation decreased 51% compared to CD9+Ctr siRNA 
(Figure 2-5C and 2-5D). However, there was no significant difference in gelatinolytic 
band intensity between Mock+Ctr siRNA and CD9+MMP-9 siRNA HT1080 cells. 
Moreover, an invasion assay was used to determine the effect of silencing MMP-9 in 
CD9-HT1080 cells. There was a 58% reduction in the invasive capabilities of 
CD9+MMP-9 siRNA HT1080 cells compared to CD9+Ctr cells (Figure 2-5E and 2-5F). 
No statistical difference was observed between the relative invasion of Mock+Ctr and 
CD9+MMP-9 siRNA HT1080 cells. These results support the concept that the expression 
of MMP-9 elicited by overexpression of CD9 is responsible for the observed invasive 
phenotype of CD9-HT1080 cells. 
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Figure 2-5. Silencing MMP-9 in CD9-HT1080 cells is sufficient to suppress the invasive phenotype. 
CD9-HT1080 cells were transiently transfected with short-interfering RNA directed to MMP-9 (CD9 + MMP-9 siRNA). Likewise, 
Mock- and CD9- HT1080 cells were transfected with a scrambled siRNA as a negative control (Mock + Ctr siRNA or CD9 + Ctr 
siRNA). (A) qRT-PCR analysis was used to measure changes in MMP-9 mRNA levels among Ctr and MMP-9 siRNA transfected 
cells. (B) Changes in release of MMP-9 (ng/ml) in to the cleared culture supernatant were examined using a MMP-9 specific ELISA 
kit. (C) Pro-MMP-9 levels in the supernatants of transiently transfected cells was measured using gelatin zymography and (D) 
quantified by densitometry. (E) A representative image of cells invading though matrigel after transfection with siRNA. (F) Percent 
cell invasion through matrigel-coated inserts after 20 hours was quantified and the results were normalized to Mock + Ctr siRNA 
treated cells *, p<0.05; **, p<0.001. 
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CD9 Second Extracellular Loop Contributes to Increases in MMP-9 Expression  
 
 Multiple independent groups have attributed a myriad of functions to the EC2 of 
CD9. CD9 EC2 has been demonstrated to be responsible for association with heparin-
binding epidermal growth factor-like growth factor [106, 107], cell motility [37, 108], 
cell-adhesion and fibronectin matrix assembly [108, 109], association with other 
tetraspanins [110], and association with transmembrane TGFα [111]. Consideration of 
these findings led to the hypothesis that increases in MMP-9 expression and release into 
the media may be attributed to the highly functional CD9 EC2. Wild-type HT1080 were 
stably transfected with a CD9 mutant lacking EC2 amino acids 173-192 (Δ6-HT1080). 
Primers were designed to detect the levels of mRNAs that code for the amino acids at the 
N-terminal and first transmembrane region (TM1; amino acids 5 to 35) and the CD9 EC2 
(EC2; amino acids 158-185). Upon transfection, CD9 EC2 mRNA in Δ6-HT1080 cells 
was undetectable; however, the levels of CD9 EC2 mRNA were not significantly 
different between Mock- and Δ6-HT1080 cells (Figure 2-6A). CD9 TM1 mRNA levels 
were not significantly different between CD9- and Δ6-HT1080 cells (Figure 2-6B) 
Confirmation of CD9 EC2 deletion mutant cell surface expression was assessed by flow 
cytometry. As seen in the left column of Figure 2-6C, the binding of mAb7 – a 
monoclonal antibody specific for CD9 EC2 – was similar for both Mock- and Δ6-
HT1080 cells. Binding of the anti-CD9 EC1 antibody, Rap2, was not detectable in Mock-
HT1080 cells, but was similar in CD9- and Δ6-HT1080 cells (Figure 2-6C, middle 
column). Anti-CD151 antibody bound similarly to all three cell lines (Figure 2-6C, right 
column). 
 
 MMP-9 mRNA levels were 7.8 fold lower in Δ6-HT1080 compared to CD9-
HT1080 cells (p<0.001; Figure 2-7A). MMP-2 mRNA levels between Δ6-HT1080 and 
CD9-HT1080 cells were unchanged. The concentration of MMP-9 in the supernatant of 
Δ6-HT1080 cells (11.9±1.6 ng/ml) was not significantly different from Mock-HT1080 
revealed earlier (16.9±3.5 ng/ml). Quantification of MMP-9 gelatin degradation of Δ6-
HT1080 cells was 33% lower than degradation observed in CD9-HT1080 cells (Figure 
2-7B and 2-7C). There was no significant difference in pro-MMP-9 gelatinolytic band 
intensity between Mock- and Δ6-HT1080 cells, and pro-MMP-2 degradation was similar 
among all three treated cells. A matrigel invasion assay using these cell lines revealed 
that Δ6-HT1080 cells were significantly less invasive than CD9-HT1080 cells (Figure  
2-7D and 2-7E). There was no significant difference between the invasive properties of 
Mock- and Δ6-HT1080 cells. These data suggest a specific role for the second 
extracellular loop of CD9 in the induction of MMP-9 expression, release, and 
degradation. 
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Figure 2-6. Characterization of the second extracellular loop (EC2) deletion mutant of CD9 in HT1080 cells. 
Upon transfection with the EC2 deletion mutant in HT1080 cells, mRNA expression was measured using primer pairs specific for the 
nucleotides coding the EC2 (A) and TM1 (B) regions of CD9. (C) Flow cytometric analysis of Mock-, CD9-, and Δ6-HT1080 cells is 
indicated by each row, and each column indicates CD9 EC2 (mAb7), CD9 TM1 (Rap2), or CD151 binding (shaded histograms) **, 
p<0.001. 
CD9 EC1 CD9 EC2 
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Figure 2-7. An increase in MMP-9 expression and release and subsequent cell 
invasion requires the second extracellular loop (EC2) of CD9. 
(A) MMP-9 mRNA expression was measured in Mock-, CD9-, and Δ6-HT1080 cells 
using qRT-PCR (B,C) Release of pro-MMP-9 and pro-MMP-2 was measured by gelatin 
zymography and quantified using Image J. (D,E)  A representative picture of cell 
invasion through matrigel coated inserts and relative quantification of cell invasion *, 
p<0.05; **, p<0.001. 
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CHAPTER 3.    PRO-MMP-9 UPREGULATION IN HT1080 CELLS 
EXPRESSING CD9 IS REGULATED BY EPIDERMAL GROWTH FACTOR 
RECEPTOR† 
 
 
Rationale 
 
 The observed attenuation of CD9-mediated increase in the expression and release 
of pro-MMP-9 in the absence of EC2 warranted further exploration. Interestingly, CD9 
has been demonstrated to associate with epidermal growth factor (EGF) receptor (EGFR) 
and regulate its activity; however, CD9 regulation of EGFR is not entirely clear. EGFR 
expression and activity was strongly connected to the augmentation of MMP-9 
expression in multiple reports [112-115], and previous work in a HT1080 model system 
demonstrated CD9 co-immunoprecipitated with EGFR [94]. Consequently, it was 
hypothesized that CD9 EC2 may regulate MMP-9 expression via EGFR. 
 
 
Materials and Methods 
 
 
Reagents and Antibodies 
 
 The reagents used in this chapter were similar to those used in the Material and 
Methods section of Chapter 2. The anti-EGFR antibody (4267) was purchased from Cell 
Signaling Technologies (Danvers, MA). The horseradish peroxidase (HRP)-conjugated 
secondary antibodies anti-rabbit (NA934VS) and anti-mouse (NA931VS), and molecular 
weight marker (RPN800E) were purchased from GE Healthcare (Pittsburgh, PA). 
Receptor tyrosine kinase inhibitors sunitinib (S-8803), gefitinib (G-4408), erlotinib (E-
4997), lapatinib (L-4804) and AG1478 (T-7310) were purchased from LC laboratories 
(Woburn, MA). 
 
 
Western Blot 
 
 All lysates were made in a TX-100 lysis buffer (1% TX-100, 20mM tris-HCl, 
150mM NaCl, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate) including protease 
(P8340) and phosphatase inhibitor cocktails (P0044, P5726) purchased from Sigma 
Aldrich. Lysate concentration was determined using a colorimetric Bradford Assay 
(Pierce, Thermo Scientific, Rockford, IL) and a standard curve generated by dilutions of 
bovine serum albumin (BSA). Absorbance measurements were obtained using a 
VersaMax tunable microplate reader at 750nm (Molecular Devices, Sunnyvale, CA). 
                                                 
 
† Adapted with permission from Biochemical and Biophysical Research Communications: Herr MJ, Mabry 
SE, Jameson JF, Jennings LK (2013) Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is 
regulated by epidermal growth factor receptor. Biochem Biophys Res Commun. 
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Protein concentrations for each sample were determined by comparison to the standard 
curve.  
 
 Equal concentrations of lysate mixed with reducing or non-reducing buffer were 
loaded onto a SDS-polyacrylamide gels of differing percentages depending on proteins of 
interest. The gels were run in a tray buffer with a final concentration of 50mM Tris-HCl, 
200mM glycine, and 0.1% (w/v) sodium dodecyl sulfate (SDS) pH 8.3. The proteins 
were transferred to a polyvinyl difluoride (PVDF) membrane in a buffer containing 
25mM Tris-HCl, 200mM glycine, 1% SDS, and 20% (v/v) methanol. After the transfer, 
non-specific sites of binding were blocked using 5% (w/v) BSA in Tris-buffered saline 
with 1% (v/v) Tween-20 (TBST) solution. Anti-human CD9 (mAb7, 1:500), anti-human 
total EGFR (1:5,000), or anti-human β-tubulin (1:20,000) was diluted in 5% BSA-TBST 
and incubated overnight at 4oC. After washing off the primary antibody with TBST, a 
HRP-conjugated anti-mouse antibody (1:5,000) for mAb7 or anti-rabbit antibody 
(1:50,000) for EGFR and β-tubulin was diluted in 5% BSA-TBST, added to the blots, and 
incubated for 1 hour at room temperature. The blots were again washed as described 
earlier and incubated with Pierce ECL 2 Western blotting substrate for 5 minutes. X-ray 
film was used to detect chemiluminescence and the films were developed using a Konica 
Minolta X-ray machine. Band density was determined using NIH ImageJ software, and 
mAb7 band densities were normalized the corresponding to β-tubulin band densities. 
 
 
Receptor Tyrosine Kinase Inhibitor Treatment 
 
 Each inhibitor was reconstituted in DMSO to the following stock concentrations: 
sunitinib 50μM, gefitinib 100μM, erlotinib 100μM, lapatininb 100μM, and AG1478 
100μM. These stock concentrations were further diluted using DMSO and added to 2 ml 
of serum-free DMEM and cell mixture to get a final concentration of 10μM, 5μM, or 
1μM inhibitor with an equivalent final volume of DMSO for each treatment. Likewise, 
the same volume of DMSO without inhibitor was added to the cells as a negative control. 
The cells and DMSO or diluted inhibitor were incubated for 30 min at 37°C, then added 
to the FN-coated wells and placed in the incubator for 24 hours. After 24 hours, no 
difference in cell confluence was observed between the different treatments. 
 
 
Knockdown of EGFR in HT1080 Cells 
 
 Small interfering RNA (siRNA) targeting EGFR was ordered from Cell Signaling 
Technology (#6480). A non-specific, scrambled siRNA (AM4635) purchased from 
Ambion (Life Technologies, Grand Island, NY) was used as a control. Prior to 
transfection, 10μl of Lipofectamine 2000 was incubated to 0.5 ml of serum-free DMEM 
for 5 minutes at room temperature and 600 pmol of siRNA in 0.5 ml of serum-free 
DMEM was added to Lipofectamine dilution and allowed to incubate for 20 minutes. 
HT1080 cells were 70% confluent upon transfection, and cell monolayers were washed 
three times with PBS, and then 1 ml of Lipofectamine-siRNA mixture was added drop 
wise to the cells in a 6-well cell culture plate. After 6 hours, the mixture was aspirated 
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and monolayers were rinsed with serum-supplemented DMEM and allowed to incubate 
for 24-48 hours before preforming experiments. 
 
 
RNA Extraction and qRT-PCR Analysis 
 
 RNA extraction and qRT-PCR analysis was performed as detailed in the 
Materials and Methods section of Chapter 2. The same primers listed in Table A-1 were 
used for analysis with the addition of the EGFR primer listed in Table A-3. 
 
 
Statistical Analysis 
 
 Sample testing and statistical analysis was performed as detailed in the Materials 
and Methods section of Chapter 2. 
 
 
Results 
 
 
Inhibiting EGFR Signaling Decreases Pro-MMP-9 Release from CD9-HT1080 Cells 
 
 Protein levels of CD9 expression were confirmed using an anti- human CD9 
monoclonal antibody (mAb7) with Western blot (Figure 3-1A). The presence of CD9 in 
the Mock-HT1080 cells was only evident upon prolonged blot exposure (data not 
shown).Pro-MMP-9 expression in CD9-HT1080 cells was significantly attenuated upon 
treatment of the cells with a broad spectrum tyrosine kinase inhibitor, sunitinib, and was 
dose dependent (Figure 3-1B). Quantification of gelatin degradation revealed a 
significant decrease in CD9-HT1080 cells treated with sunitinib at 5 and 10μM 
concentrations. Further investigation on the role of EGFR in pro-MMP-9 release was 
carried out using multiple tyrosine kinase inhibitors with previously demonstrated 
specificity for EGFR. Getfitnib, erlotinib, lapatinib, and AG1478 all demonstrated a 
dose-dependent inhibition of pro-MMP-9 release in CD9-HT1080 cells (Figure 3-2A 
through 3-2D). Moreover, CD9-HT1080 cells were significantly less invasive through 
matrigel after treating with 10μM of gefitinib (Figure 3-2E). These findings show that 
CD9 augments pro-MMP-9 release and subsequent cell invasion through matrigel via 
EGFR activation. 
 
 
Knockdown of EGFR in CD9-HT1080 Cells Attenuates the Release of Pro-MMP-9 
and Subsequent Cell Invasion 
 
 Upon discovering that inhibiting EGFR signaling negatively regulated the CD9-
mediated increase in pro-MMP-9 release, EGFR expression was explored as a possible 
mediator. siRNA directed against EGFR was used to knock down EGFR expression in 
CD9-HT1080 cells and a scrambled (Ctr) siRNA was used as a control treatment. 
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Figure 3-1. CD9-HT1080 cells release less pro-MMP-9 after treatment with a 
broad spectrum receptor tyrosine kinase inhibitor sunitinib. 
(A) The expression of CD9 in HT1080 cells was assessed by Western blot analysis. (B) 
Pro-MMP-9 release into serum-free media of HT1080 cells plated on 10μg/ml FN for 24 
hrs was measured using gelatin zymography as described in the materials and methods. 
Gelatinolytic activity was quantitated by measuring band intensity over three independent 
repeats. Data are presented as mean ± SD (**p<0.01). 
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Figure 3-2. Epidermal growth factor receptor tyrosine kinase inhibitors reduce 
the expression of pro-MMP-9 and inhibit CD9-HT1080 cell invasion. 
(A-D) Pro-MMP-9 gelatinolytic activity of Mock and CD9-HT1080 cells treated with 
DMSO or EGFR specific tyrosine kinase inhibitors gefitinib, erlotinib, lapatinib, and 
AG1478, respectively, was measured after 24 hrs on FN using gelatin zymography and 
quantitated. Data are presented as mean ± SD (*p<0.05, **p<0.05). (E) Representative 
images of matrigel invasion assays used to assess cellular invasion in Mock and CD9-
HT1080 cells treated with DMSO or gefitinib after 20 hours. Cells that invaded through 
matrigel were fixed and stained with crystal violet. Quantitation of the number of 
invasive cells per field of view is presented in the bar graph below (**p<0.05). 
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The mRNA and protein levels of CD9 were not affected by Ctr or EGFR siRNA 
treatment. However, total EGFR mRNA levels were significantly decreased in the EGFR 
siRNA treated CD9-HT1080 cells and were not affected upon treatment with Ctr siRNA 
(Figure 3-3A). MMP-9 mRNA levels were also significantly decreased in the EGFR 
siRNA treated CD9-HT1080 cells compared to the Ctr siRNA treated CD9-HT1080 cells 
(Figure 3-2A). The protein levels of CD9 in the CD9-HT1080 cells were unaffected by 
treatment with EGFR siRNA (Figure 3-3B). Total EGFR levels were similar between the 
Mock and CD9-HT1080 cells treated with Ctr siRNA, but were less in CD9-HT1080 
cells treated with EGFR siRNA (Figure 3-3B). Because CD9 and EGFR were 
demonstrated to co-immunoprecipitate from HT1080 cells [94], any changes in the cell 
surface expression of CD9 upon knockdown of EGFR were evaluated using flow 
cytometry. There were no significant differences in CD9 cell surface expression as a 
consequence of EGFR knockdown in CD9-HT1080 cells (Figure 3-3C). Thus, any 
phenotypic changes may be attributed to total EGFR expression levels or signaling events 
and not to changes in CD9 expression or localization. 
 
 Pro-MMP-9 release into the media and cellular invasion changes were assessed 
after treatment with Ctr and EGFR siRNA using gelatin zymograms and matrigel 
invasion assays, respectively. Upon knockdown of EGFR, there were significantly 
decreased levels of pro-MMP-9 released into the media of cells as demonstrated by 
gelatin degradation (Figure 3-3D). Furthermore, the CD9-HT1080 cells lacking EGFR 
were significantly less invasive than their Ctr siRNA treated CD9-HT1080 cells (Figure 
3-3E). These results indicated that the absence EGFR in CD9-HT1080 cells was 
sufficient to decrease MMP-9 mRNA and protein levels, and this absence reduced CD9-
HT1080 invasion without affecting the mRNA, protein, or cell surface levels of CD9. 
 
 Conclusively, the expression of CD9 augments the invasive phenotype of human 
fibrosarcoma cells by upregulating pro-MMP-9 expression and release. This phenomenon 
is specifically coordinated by the second extracellular loop of CD9 and involves 
epidermal growth factor receptor expression and activity. 
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Figure 3-3. Knockdown of EGFR results in decreased pro-MMP-9 expression and 
release without affecting the expression or localization of CD9. 
(A) The fold change in mRNA expression of CD9, EGFR, and MMP-9 in Mock and 
CD9-HT1080 cells treated with Ctr or EGFR siRNA was measured using qRT-PCR. (B) 
Protein expression of CD9 and total EGFR expression was measured using Western blot 
analysis of Mock and CD9-HT1080 cell lysates treated with Ctr or EGFR siRNA. (C) 
Flow cytometric analysis of nonpermeabilized Mock and CD9-HT1080 cells for CD9 
expression after treatment with Ctr or EGFR siRNA. Dotted line represents non-specific 
mIgG binding, light-gray shaded histogram is mAb7 (anti-CD9) staining of Mock + Ctr 
siRNA, dark gray shaded histogram is mAb7 staining of CD9 + Ctr siRNA, and the solid 
line unshaded histogram is mAb7 staining of CD9 + EGFR siRNA. (D) Pro-MMP-9 
release in to the cell media after treatment with Ctr or EGFR siRNA was assessed using 
gelatin zymography. (E) Matrigel invasion assay of Mock and CD9-HT1080 cells after 
treatment with Ctr or EGFR siRNA and quantification of the average number of cells that 
invaded per field of view. Bar graphs represent mean ± SD (*p<0.01, **p<0.05). 
  
IgG 
Mock + Ctr si 
CD9 + Ctr si 
CD9 + EGFR si 
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CHAPTER 4.    CD9 CONTRIBUTIONS TO CANCER CELL BIOLOGY*† 
 
 
 An invasive and metastatic human carcinoma cell line was used to explore the 
contribution of tetraspanin CD9 to tumor cell invasion. Typical tetraspanin cell surface 
density is between 30,000 to 100,000 copies per cell [19, 28, 116]. Although the exact 
number of CD9 molecules on the cell surface was not determined, CD9 expression in 
CD9-HT1080 cells at the mRNA and cell surface levels was similar to the previously 
published endogenous expression of CD9 in other cancerous cell lines including colon 
[117] and non-small cell lung cancer [70].  
 
 Tetraspanins function at the cell surface through organizing multimolecular 
complexes composed of tetraspanins and associating molecules, including integrins [1, 
118]. Upon expression of a single tetraspanin, the expression levels of other tetraspanins 
or integrins may fluctuate at the mRNA or cell surface level to compensate for 
microdomain organization. This rarely explored phenomenon may explain why CD9 
function in various cancer cell lines is not fully congruent [74, 97, 119]. The studies here 
indicate increased CD9 at the cell surface level was not sufficient to stimulate or suppress 
mRNA expression of other integral members within the functional tetraspanin-enriched 
microdomain. The cell surface expression of other tetraspanin members that play 
prominent roles in cancer cell invasion including CD63 [120], CD81 [90, 105, 121], and 
CD151 [122-124] were unaffected by CD9 overexpression. These findings suggest the 
increased invasive phenotype of CD9-HT1080 cells may be attributed primarily to 
increases in CD9. 
 
 Interestingly, there was a significant decrease in the cell surface levels of both α2 
and β1 integrins in CD9-HT1080 cells compared to Mock cells. CD9 expression may 
slightly downregulate the cell surface expression of the α2β1 integrin subunit thus 
affecting MMP-1 expression. There is convincing evidence that MMP-1 expression is 
induced only in osteogenic cell lines that express α2β1 [125]. Moreover, blockade with 
either MMP-1 or α2 antibodies significantly decreased keratinocyte migration, indicating 
that α2 may regulate MMP-1 expression [126]. Decreased MMP-1 mRNA expression 
observed in CD9-HT1080 cells may be related to reduced α2β1 cell surface expression. 
In spite of that, the findings at the mRNA level did not fully translate to a significant 
decrease in MMP-1 proteinase release in the cell supernatant as determined by ELISA. 
This finding led to the exclusion of α2β1 or MMP-1 as mediators of the phenotypic 
differences between Mock- and CD9-HT1080 cells. 
 
                                                 
 
* Adapted with permission from Public Library of Science. Herr MJ, Kotha J, Hagedorn N, Smith B, 
Jennings LK (2013) Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via 
upregulation of matrix metalloproteinase-9. PLoS One 8: e67766. 
† Adapted with permission from Biochemical and Biophysical Research Communications: Herr MJ, Mabry 
SE, Jameson JF, Jennings LK (2013) Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is 
regulated by epidermal growth factor receptor. Biochem Biophys Res Commun. 
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 The invasive phenotype observed in CD9-HT1080 cells was the result of 
significant increases in MMP-9 mRNA expression and proteinase release into the media. 
This conclusion was endorsed by the fact that silencing MMP-9 in CD9-HT1080 reverted 
the invasive phenotype of these cells to mimic that of the Mock-transfected cells. An 
earlier study did not observe this invasive phenotype in CD9-HT1080 cells using a 
matrigel invasion assay [71]. This difference may be the result of higher cell numbers and 
increased chemoattractant the earlier study used in the invasion assays, which would have 
overwhelmed the possibility of observing any differences in cell invasion. However, 
when using conditions more similar to this report’s experimental design, Zvieriev et al. 
demonstrated that exogenous CD9 expression increased in vitro matrigel invasion in a 
prostate cancer cell line [127]. A recent study corroborated the finding that silencing of 
MMP-9 in HT1080 cells decreases their invasive capabilities both in vitro and in a 
xenograft model of invasion [128].  
 
 Other laboratories have demonstrated that tetraspanin expression may indirectly 
result in the regulation of MMP production by influencing TIMP expression and activity. 
Jee and colleagues demonstrated that KAI1/CD82 upregulated TIMP-1 to suppress tumor 
cell invasion in lung carcinoma model [129]. TIMP-1 complexes with pro-MMP-9 and 
inhibits its conversion to the active proteinase [130]. Furthermore, tetraspanin CD63 
interacts with TIMP-1 at the cell surface to regulate cell survival and apoptosis in a breast 
epithelial cell line [89]. All four TIMP expression levels were compared between Mock 
and CD9-HT1080 cells. TIMP-4 expression was not detectable in either Mock- or CD9-
HT1080 cells ruling out its contributions. This finding is most likely due to the fact that 
TIMP-4 expression is prominent only in the brain, heart, ovary, and skeletal muscles of 
adult mice [131] and was originally isolated in the human heart with very low or absent 
levels of expression in other major organs [132]. The absence of a significant change in 
the mRNA expression of TIMP-1, TIMP-2, or TIMP-3 upon CD9 overexpression favors 
the idea that CD9 expression does not regulate MMP expression via changes in TIMP 
mRNA levels. 
 
 Strong evidence involves PI3K-Akt [133-136] signaling preceding MMP-9 
increases in cancer cell lines. This pathway signals to the downstream transcription 
factors NF-κB [133, 137] and AP-1 [138, 139] to increase MMP-9 production. 
Specifically, Thant, et al. found the PI3K-Akt pathway to be essential for FN-dependent 
MMP-9 secretion and invasion of ovarian cancer cells [140]. LY294002, wortmannin, 
and a dominant-negative Akt construct blocked MMP-9 production in multiple human 
hepatocellular carcinoma cell lines [133]. MMP-9 production was stimulated through the 
PI3K, Akt, JNK1/2 pathway in human limbal epithelial cell outgrowth and was not 
affected by MEK1/2 or p38MAPK inhibition [141].Lisa Jennings and colleagues 
previously demonstrated in two cell lines that CD9 expression enhances Akt 
phosphorylation [142, 143]. Both of the CD9-elicited phenotypes were nullified upon 
treatment with LY294002 or wortmannin [142, 143]. Preliminary studies with CD9-
HT1080 cells indicated a 25% decrease in MMP-9 gelatinolytic band intensity using the 
PI3K inhibitor LY294002 in a gelatin zymography analysis of CD9-HT1080 conditioned 
media (Herr et al., unpublished observations). The same PI3K-Akt pathway may be 
responsible for the observed increase in MMP-9 expression and secretion in CD9-
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HT1080 cells. Chen, et al. substantiate this hypothesis by demonstrating that CD9 
expression in HT1080 cells resulted in increased Akt phosphorylation [94]. 
 
 The second extracellular loop (EC2) of CD9 is responsible for the upregulation of 
diphtheria toxin binding [58], and gamete fusion [57]. Deletion of CD9 EC2 in a CHO 
cell line led to decreased motility and increased cell adhesion and fibronectin matrix 
assembly [103, 108]. Herein, it was demonstrated that CD9 EC2 was critical in eliciting 
MMP-9 expression in CD9-HT1080 cells. Upon EC2 deletion, the observed increases in 
MMP-9 expression and release were reduced to levels found in Mock-HT1080 cells or 
after silencing of the proteinase. Furthermore, the increase in the invasive phenotype of 
CD9-HT1080 cells was reduced upon deletion of CD9 EC2. These findings confirm and 
extend previously published data that CD9 EC2 is of immense importance in the full 
functioning of this tetraspanin.  
 
 It is well-established that EGFR activation results in increased MMP-9 expression 
and release [112, 144] and that MMP-9 expression results in increased cell invasion [133, 
145]. The mechanism for how CD9 may regulate MMP-9 expression is not entirely clear. 
Murayama et al. demonstrated that the EC2 of CD9 associates with EGFR and β1 
integrin. Treatment with an anti-CD9 monoclonal antibody, ALB6, enhanced EGFR 
internalization after EGF treatment [93]. ALB6 has been reported as an inhibitory 
antibody to CD9 [73, 146-148]; therefore, inhibition of CD9 resulted in increased EGFR 
internalization. In the same study, CD9 and EGFR expression in Chinese hamster ovary 
cells (CHO) resulted in increased receptor internalization upon EGF treatment [93]. 
Hence, these findings were severely confused by the fact that CD9 inhibition and 
overexpression had the same outcome. To further befuddle this mechanism, another 
group demonstrated that CD9 does not associate with EGFR, but regulates EGFR 
juxtacrine signaling in HEK293 cells by associating with the transmembrane EGFR 
ligand TGFα [111]. 
 
 The findings in this current report showed that CD9 regulated the release of pro-
MMP-9 in HT1080 cells via EGFR expression and activity. EGFR activity was proved 
necessary using four distinct EGFR tyrosine kinase inhibitors. All inhibitors 
demonstrated a dose-dependent inhibition of pro-MMP-9 indicating their specificity. 
Treatment with 10μM gefitinib inhibited pro-MMP-9 release to a level comparable to 
Mock-HT1080 cells. For this reason, the same concentration of gefitinib was used to 
suppress CD9-HT1080 cell invasion. Inhibition of EGFR activity with gefitinib was 
sufficient to inhibit pro-MMP-9 release which resulted in decreased cellular invasion in 
CD9-HT1080 cells. The expression of total EGFR protein in Mock, CD9, and Δ6 
HT1080 cells was not significantly different as determined by Western blot (Figure  
3-3B, unpublished observations). Correspondingly, the regulation of EGFR signaling 
must be at the level of cell surface receptor expression and at the level of EGFR 
phosphorylation (activity). The experimental design of plating the cells on FN in serum-
free media was similar to multiple other studies that demonstrated ECM-mediated 
activation of EGFR in the absence of EGFR ligands [149-151]. Kotha, et al. established 
that CD9 associates with integrin α5β1 using co-immunoprecipitation in multiple cell 
lines and that it plays a role in enhancing the activation state of β1 integrins [142, 143]. 
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Full-length CD9 expression may stabilize CD9-α5β1 interactions with fibronectin and 
augment ECM-mediated EGFR activation to stimulate increased pro-MMP-9 release.  
 
 Moro et al. conducted an elaborate study to tease out how integrins may activate 
EGFR in the absence of EGFR ligands [151]. When an α-associated β1 integrin subunit is 
engaged either by antibody treatment or ECM, the activated α subunit associated with 
autophorphorylated cSrc and the β1 subunit cytoplasmic tail associates with 
phosphorylated p130Cas [151]. It was hypothesized that active cSrc then phosphorylates 
EGFR at tyrosine 845 [151]. The phosphorylated EGFR is then brought into a complex 
with the α and β1 integrin subunits and autophosphorylation of EGFR occurs and 
downstream signaling commences [151]. Studies from the Jennings’ laboratory nicely 
assimilate the findings from this paper and the CD9- α5β1-EGFR proposed signaling 
mechanism. First, CD9 expression increased the phosphorylation of p130Cas upon 
binding fibronectin [142]. CD9 expression also intensified β1 integrin subunit activation 
in response to FN [142]. Second, CD9 EC2 was elegantly demonstrated to bind directly 
to FN and promote the CD9-FN-induced motile phenotype [108] . Thus, CD9 may not 
only serve to regulate β1 integrin confirmation but also bring the triad in closer proximity 
to FN. Consequently, in the absence of CD9 (Mock-HT1080 cells) or when CD9 is not 
associated with α5β1 integrin or helping to bind FN (Δ6-HT1080 cells), EGFR signaling 
is weakened. Therefore, pro-MMP-9 expression and release, and cell invasion would not 
be increased over baseline invasion. The same results were observed when EGFR 
activation was inhibited using EGFR-specific tyrosine kinase inhibitors and when EGFR 
expression was decreased using siRNA. In summary, it is hypothesized that CD9 
regulates EGFR signaling in HT1080 cells by a CD9- α5β1-FN interaction that stimulates 
EGFR phosphorylation. 
 
 The pitfall to this hypothesis is that EGFR largely signals downstream through the 
p38MAPK, ERK pathway [152, 153], but previous findings suggest PI3K is the major 
downstream signaling pathway from CD9 expression [142, 143]. Although MMP-9 
expression is primarily evoked through the PI3K pathway, there is sufficient evidence to 
suggest ERK signaling may also elicit MMP-9 expression [154-156]. The most 
imaginable scenario is that signaling to MMP-9 occurs through both pathways. 
Supporting evidence from Sil et al. demonstrated that adhesion to FN induced MMP-9 
mRNA, protein, and activity in murine melanoma cells via the alpha5beta1 integrin and 
the FAK, ERK, and PI3K pathways [157]. Preliminary data in this laboratory suggest 
treatment of CD9-HT1080 cells with U0126 and PD98059 to block pro-MMP-9 release 
to levels comparable with Mock-HT1080 cells (Figure B-3). Cell signaling is a very 
dynamically regulated process especially at the cell-ECM junction. CD9’s partnership 
with multiple different proteins is cell type specific, but in HT1080 cells CD9 has been 
demonstrated to co-immunoprecipitate EGFR. 
 
 In summary, these findings demonstrate for the first time a specific link between 
tetraspanin CD9 and metalloproteinase MMP-9 expression that significantly affects the 
invasive phenotype of HT1080 cells. Therefore, CD9 consequently may play an 
important role in tumor cell invasion and promoting metastasis. This potential 
relationship between CD9 expression and the tumor cell phenotype is supported by 
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studies that used inhibitory anti-CD9 antibodies to decrease tumor weight in two separate 
in vivo models [73, 147]. Additionally, the CD9 EC2 region is a potentially new target 
for regulating MMP-9 production. Together, these key findings support a model in which 
tetraspanin CD9 may have considerable therapeutic potential for the treatment of 
metastasizing cancers. 
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CHAPTER 5.    TETRASPANIN CD9 REGULATES CELL CONTRACTION AND 
ACTIN ARRANGEMENT IN HUMAN AORTIC SMOOTH MUSCLE CELLS 
VIA RHOA 
 
 
Introduction 
 
 Smooth muscle cells (SMCs) located in the medial layer of the arterial wall are 
primarily responsible for regulating the physiomechanical properties of arteries. These 
cells are unique in that they are not terminally differentiated and retain their ability to 
transform their phenotype from contractile or differentiated to synthetic or 
dedifferentiated. The switch from a contractile to synthetic phenotype is a well-studied, 
though complex, occurrence and is primarily characterized by a change in cell 
morphology from elongated to more rounded cells and by a decrease in smooth muscle 
cell marker expression [158]. Vascular smooth muscle cells (VSMC) in the synthetic 
state are associated with coronary artery disease including atherosclerosis and restenosis 
as well as with hypertension 
 
 Understanding the mechanisms that control VSMC phenotype switching during 
vascular development and in vascular disease is an intense area of investigation. The 
importance of cell surface proteins, specifically integrins and tetraspanins, and their 
regulation of interactions with the extracellular matrix (EMC) have been previously 
demonstrated to play a relevant role in vascular cell biology [159, 160]. Tetraspanins 
function primarily as cell surface organizers and play an integral role in the potentiation 
of cellular responses from the extracellular environment. It has been demonstrated that 
the action of integrins is dependent on their interaction with tetraspanins [161]. 
Tetraspanins are ubiquitously expressed in vascular and hematopoietic cells and have 
implications in multiple physiologic and pathologic functions, yet they are understudied 
in the field of vascular biology [160].  
 
 Tetraspanin CD9 has been implicated in multiple essential cellular processes 
relevant to the smooth muscle cell synthetic phenotype including proliferation [111], 
migration [162], and neointimal formation [143]. Specifically, this laboratory and others 
previously demonstrated an elevated expression level of tetraspanin CD9 on the cell 
surface of cultured VSMCs in the synthetic state [143, 163]. The expression of CD9 was 
closely linked to the dedifferentiated phenotype of smooth muscle cells. Blockade or 
stimulation of CD9 using monoclonal antibodies resulted in the propagation or 
modulation of these phenotypes; however, there has not been an explanation as to how 
CD9 regulates the phenotypic diversity of these cells [103, 164]. 
 
 
Rationale 
 
 The present study was designed to further determine the role CD9 plays in 
regulating the dedifferentiated phenotype of smooth muscle cells. A human model of 
arterial function,  human aortic smooth muscle cells (HAOSMC), was used to specifically 
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understand the importance of  CD9 on human VSMC phenotypes, namely the capability 
of the cells to undergo contraction. CD9 knockdown resulted in pronounced morphologic 
changes and altered cellular actin arrangement. Furthermore, lack of CD9 reduced the 
highly coordinated contractile capabilities of HAOSMC. GTP-bound RhoA (active 
RhoA) levels were significantly diminished in cells lacking CD9. Restoration of RhoA 
activity in the CD9 deficient cells was sufficient to restore the contractile phenotype. 
Conversely, inhibition of active RhoA or knockdown of total RhoA resulted in a 
phenotype that mimicked CD9 deficient cells. The reported results outline a previously 
unexplained mechanism by which CD9 has a key role in regulating SMC contraction and 
SMC phenotypes. 
 
 
Materials and Methods 
 
 
Reagents and Antibodies 
 
 Smooth muscle cell basal medium (SmBM), fetal bovine serum (FBS), 
recombinant human epidermal growth factor (rhEGF), recombinant human fibroblast 
growth factor (rhFGF), recombinant human insulin, and gentamicin sulfate/amphotericin-
B purchased from Lonza (CC-3182, Walkersville, MD). Alexa-fluor 594 conjugated 
phalloidin (A12381) and Lipofectamine 2000 was purchased from Life Technologies 
(Grand Island, NY). The RhoA activator (CN03) and the RhoA inhibitor (CT04) were 
purchased from Cytoskeleton (Denver, CO). Information pertaining to the antibodies 
used in this chapter may be found in chapter 2. 
 
 
Cell Culture 
 
 Primary human aortic smooth muscle cells (HAOSMC) were purchased from 
Lonza at passage 3. HAOSMC were cultured in a humidified incubator at 37°C and 5% 
CO2 in SmBM containing a final concentration of 5% FBS, 0.5 ng/ml rhEGF, 2 ng/ml 
rhFGF, 5 μg/ml insulin, and 50 μg/ml gentamicin sulfate/amphotericin-b (serum-
supplemented SmBM). Cells were maintained in the synthetic state by changing media 
every 48 hours and passaging every 96 hours. 
 
 
Knockdown of CD9 in HAOSMC Cells 
 
 CD9 lentiviral shRNA was generated in the viral vector core laboratory at the 
University of Tennessee Health Science Center (UTHSC, Memphis, TN). pLKO.1 CD9 
shRNA lentiviral vector plasmids were obtained from Open Biosystems (Thermo 
Scientific, Pittsburgh, PA) and the plasmids were propagated in DH5α E. Coli in 
LB+Carbencillin containing media. pLKO.1 CD9 shRNA or scrambled control (Ctr) 
shRNA was co-transfected into 293FT cells using ViraPower mix kit (Invitrogen, Grand 
Island, NY). Cell culture supernatants were harvested 60 hours after transfection, filtered 
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through 0.45μM filters, and the lentivirus was concentrated by ultracentrifugation at 
50,000 x g for 3 hours. At passage 5, HAOSMC at 70% confluence were transduced in 6-
well culture dishes using 2 ml of serum-free SmBM containing 10μl of lentiviral shRNA 
and a final concentration of 10μg/ml polybrene. Transduction was complete after 24 
hours and selection of cells positive for shRNA constructs was performed 48 hours after 
transduction using a final concentration of 1.0μg/ml puromycin. All successive 
experiments were conducted using HAOSMC between passages 6 and 8. 
 
 
RNA Extraction and qRT-PCR Analysis 
 
 RNA extraction and qRT-PCR Analysis was performed as detailed in the 
Materials and Methods section of Chapter 2. The cDNA was made from 500ng of total 
HAOSMC RNA and additional primers used are listed in Table A-3. 
 
 
Knockdown of RhoA in HAOSMCs 
 
 Naïve HAOSMC at passage 5 were transfected with short interfering (siRNA) 
directed against RhoA (Product #4390824, ID# s758) or a scrambled control (Ctr) siRNA 
sequence (AM4635) purchased from Ambion (Life Technologies, Grand Island, NY). 
Prior to transfection 10μl of Lipofectamine 2000 was incubated in 0.5 ml of serum-free 
SmBM for 5 minutes at room temperature, then 600 pmol of siRNA in 0.5 ml of serum-
free SmBM was added to Lipofectamine dilution and allowed to incubate for 20 minutes. 
HAOSMCs were 70% confluent upon transfection, cell monolayers were washed three 
times with PBS, then 1 ml of Lipofectamine-siRNA mixture was added dropwise to cells 
in 6-well cell culture plates. After 6 hours, the mixture was aspirated and monolayers 
were rinsed with serum-supplemented SmBM and allowed to incubate for 24-48 hours 
before preforming experiments.  
 
 
Measurement of the Area of Crystal Violet Stained Cells 
 
 Control and CD9 shRNA HAOSMC plated in serum-supplemented SmBM in 24-
well culture plates were washed twice with PBS and fixed and permeabilized in ice cold 
methanol for 5 minutes. The methanol was washed off and a saturating amount of 0.05% 
crystal violet was added for 30 minutes. The crystal violet was aspirated and the cells 
were washed twice with distilled water and allowed to air dry. Pictures were then taken at 
4x and 10 x magnifications using an inverted phase contrast microscope, a Sony 3CCD 
color video camera (Tokyo, Japan) and Scion Image software (Frederick, MD). The area 
of the cells at 10x magnification was measured in arbitrary units using ImageJ software. 
This experiment was completed three independent times and a total of 25 cells from 
random fields of view from each experiment were measured to calculate the average area. 
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Proliferation Assay 
 
 Proliferation of cells in culture was measured using a bromodeoxyuridine (BrdU) 
incorporation assay purchased from Cell Signaling Technology (6813, Danvers, MA) per 
the manufacturer’s instructions. Briefly, cells were harvested, counted, and diluted to 
equal densities in serum-supplemented media and 6,000 cells were added to each well of 
a 96-well cell culture plate along with 1xBrdU. After 24, 48, or 72 hours, the media was 
aspirated and the cells were fixed and DNA was denatured. Anti-BrdU primary antibody 
was added and incubated for 1 hour. The plate was subsequently washed three times 
using 1x washing buffer and a HRP-conjugated secondary antibody was added. After a 
30 minute incubation, a 3,3’, 5,5’-tetramethylbenzidine (TMB) substrate was added for 
15 minutes then a stop solution was added to stop color development. Absorbance was 
read on a versamax tunable microplate reader at 450nm. Each group was run in triplicate 
and averaged. A total of three independent repeats for each group were performed.  
 
 
Immunofluorescent Staining of F-actin 
 
 Ctr and CD9 shRNA HAOSMC were harvested and seeded at low density onto 
glass coverslips in 6-well cell culture dishes in serum-supplemented SmBM. After two 
hours of attachment, the media was aspirated and cells were fixed in 4% 
paraformaldehyde (PFA)-PBS solution. After 10 minute incubation the 4% PFA-PBS 
solution was aspirated, and the cells were rinsed three times with PBS then permeabilized 
using 0.1% TX-100 in PBS for 5 minutes. The TX-100 solution was aspirated and the 
monolayer of cells was washed three times with 5% goat serum (GS) in PBS and 
incubated with 5% GS-PBS for 30 minutes to block any non-specific binding. Alexa-
fluor-594 conjugated phalloidin (1:50) in 5% GS-PBS was added to the coverslips and 
incubated for 30 minutes at room temperature. After aspirating and washing the 
monolayer of cells with PBS, the coverslips were inverted and mounted to glass slides 
using Vectashield hard set mounting medium (H-1400, Vector Laboratories, Burlingame, 
CA). Images were acquired using an Axioplan 2 fluorescent imaging microscope 
equipped with an AxioCam HRm camera and actin length was quantified using 
AxioVision software (Zeiss, Oberkochen, Germany). 
 
 
Detection of Total and GTP-Bound RhoA 
 
 Active and GTP-bound RhoA were measured from cell lysates using a total RhoA 
ELISA (BK150) or RhoA activation G-LISA kit (BK124) purchased from Cytoskeleton, 
Inc. (Denver, CO) per the manufacturer’s instruction. Briefly, Ctr and CD9 shRNA 
lysates were made using the provided cell lysis buffer and protease inhibitor cocktail and 
quantified using the precision red protein assay reagent by measuring the absorbance at 
600nm on the Versamax plate reader. Lysates were diluted to 0.5mg/ml using lysis buffer 
loaded on to their respective ELISA (total RhoA) or G-LISA (GTP-bound RhoA) plate 
for protein analysis. Results were obtained as absorbance values at 490nm and were 
converted to total protein levels using a standard curve obtained with each test. Samples 
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were tested in duplicate and values from at least three independent experiments were 
averaged. 
 
 
Collagen Gel Contraction Assay 
 
 Collagen gel contraction assays were purchased from Cell Biolabs (CBA-201, 
San Diego, CA) and used per the manufacturer’s instructions. HAOSMC were harvested 
and the pellet was suspended in serum-free SmBM at 2.0 x 106 cells/ml. For each assay, 
100μl of the cell suspension was mixed with 400μl of neutralized collagen solution and 
added to one well of a 24-well cell culture plate and allowed to solidify for one hour at 
37oC. After polymerization, 1ml of complete media was added to the top of each collagen 
gel. After 48 hours incubation, the gels were released by running a sterile pipette tip 
along the sides of the well. Some populations of cells were treated with either 20μg/ml 
CN03 (RhoA activator) or CT04 (RhoA inhibitor) two hours prior to release. The culture 
dish was then scanned immediately after being released (time 0, initial time point) and for 
30 minute intervals for six hours. ImageJ software was used to measure the area of each 
collagen gel and the arbitrary units (AU) for each time point were used to calculate exact 
percent contraction values from the initial time point using the following formula: [(AU 
at Initial Time Point/AU at Current Time Point)-AU at Initial Time Point]*100%. 
 
 
Statistical Analysis 
 
 Sample testing and statistical analysis was performed as detailed in the Materials 
and Methods section of Chapter 2. For the contraction assays, a repeated measures t-test 
was used to compare the changes in contraction among two groups at each time point. 
Bars or points represent the mean result and error bars represent the standard deviation of 
the mean. 
 
 
Results 
 
 
CD9 Deficiency Results in Altered Cell Morphology, Proliferation, and SMC 
Marker Expression 
 
 Smooth muscle cells in culture have augmented CD9 expression that is correlated 
to their synthetic state [143, 163]. CD9 lentiviral shRNA was used to knockdown CD9 
expression in human aortic smooth muscle cells (HAOSMC). When compared to cells 
treated with scrambled control (Ctr) lentiviral shRNA, decreased CD9 expression in the 
CD9 shRNA HAOSMC was observed at the mRNA and protein levels (Figure 5-1A and 
5-1B). More importantly, CD9 expression was reduced at the cell surface where it 
primarily functions (Figure 5-1C). The expression of a closely related tetraspanin, CD81, 
and another highly functional tetraspanin, CD151, was not affected by CD9 knockdown 
at the mRNA or cell surface levels (Figure 5-1D and 5-1E). 
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Figure 5-1. Knockdown of tetraspanin CD9 in human aortic smooth muscle cells (HAOSMCs) does not affect CD81 or 
CD151 cell-surface expression. 
(A) The fold change in CD9 mRNA in control (Ctr) shRNA and CD9 shRNA transduced cells was measured using qRT-PCR (n=5; 
*P<0.05).(B) Whole cell expression of CD9 was measured by Western blotting using an anti-human CD9 monoclonal antibody 
(mAb7). A representative blot and quantification of three independent blots is presented (*P<0.05). (C-E) Cell surface expression of 
CD9, CD81, and CD151 was measured on non-permeabilized HAOSMCs using flow cytometry. Dotted gray lines represent negative 
control IgG binding, shaded histograms represent Ctr shRNA HAOSMC, and open histograms represent CD9 shRNA binding of 
indicated anti-human tetraspanin antibodies. A representative histogram from three independent experiments is shown for each anti-
human tetraspanin antibody. 
IgG Ctr sh CD9 sh 
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 Upon knockdown of CD9 expression a profound difference in cell morphology 
was observed (Figure 5-2A). HAOSMC lacking CD9 were notably smaller as 
determined by cell area and more rounded than their Ctr shRNA treated counterparts 
(P<0.01; Figure 5-2B). Reducing CD9 expression resulted in a cell morphology that 
resembled the dedifferentiated phenotype of SMCs [165]. CD9 shRNA HAOSMC were 
also less proliferative than Ctr shRNA cells over 72 hours as determined by 
bromodeoxyuridine incorporation assays (P<0.01; Figure 5-2C). To further define the 
phenotype of CD9 shRNA HAOSMCs, the expression levels of smooth muscle cell 
markers were measured. The mRNA expression of smooth muscle α-actin (SM α-actin) 
and SM22α were not significantly different between the two groups of cells (Figure 
5-2D). However, the expression of a third smooth muscle cell marker, calponin, was 
increased 4-fold (P<0.05; Figure 5-2D). Hence, the efforts to clarify the exact phenotype 
of HAOSMC lacking CD9 were not conclusive based on the discrepant expression of 
three smooth muscle cell markers.  
 
 
CD9 Deficient HAOSMC Have Altered Actin Arrangement and Decreased 
Contractile Capabilities because of RhoA-Mediated Pathways  
 
 It was hypothesized that decreased CD9 expression and the resulting phenotype 
may be a consequence of changes in the cellular cytoskeleton. Alexa fluor-conjugated 
phalloidin and immunofluorescent microscopy were used to characterize changes in the 
stress fiber arrangement between Ctr and CD9 shRNA treated HAOSMC (Figure 5-3A). 
The CD9 shRNA HAOSMC had a more circular arrangement of significantly shorter 
actin stress fibers whereas the Ctr shRNA HAOSMC had a more elongated and parallel 
arrangement of stress fibers (P<0.01; Figure 5-3B). These findings suggested that CD9 
may elicit the drastic morphologic difference between the two cell types by regulating the 
stress fiber arrangement. 
 
 As it is well established that actin stress fiber arrangement is a direct consequence 
of RhoA activity [166, 167], the amount of total and GTP-bound RhoA in Ctr and CD9 
shRNA HAOSMC was measured using an enzyme linked immunosorbent assay. Total 
RhoA was not significantly different between the two groups (Figure 5-3C); however, 
there was significantly less active RhoA detected in the CD9 deficient cells (P<0.05, 
Figure 5-3D). A collagen gel contraction assay was used to determine if this deficiency 
had an effect on HAOSMC contraction. CD9 shRNA HAOSMC were 30% less 
contractile than their Ctr shRNA counterparts. After 1 hour, the Ctr shRNA cells were 
significantly more contractile and remained so for the entire assay (P<0.05; Figure 5-3E 
and 5-3F). The contraction of both groups began to plateau after 4 hours and was 
unchanged at the conclusion of the assay. 
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Figure 5-2. CD9 deficient HAOSMCs have an altered cell morphology, decreased 
cell size and proliferation, and an increased level of calponin mRNA. 
(A) Knockdown of CD9 results in smaller and more rounded cells as demonstrated by 
representative phase contrast images of crystal violet stained cells at different 
magnifications (n=4 independent repeats; scale bar, 100μm). (B) Quantification of cell 
area of Ctr and CD9 shRNA HAOSMCs (n=25 cells; **P<0.01). (C) HAOSMCs lacking 
CD9 are less proliferative after 24, 48, and 72 hours in culture as measured by 
absorbance values obtained from a BrdU incorporation assay (n=5; **P<0.01 versus Ctr 
shRNA at same time point). (D) mRNA levels of SM α-actin, SM22α, and calponin were 
measured using qRT-PCR (n=3; *P<0.05). 
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Figure 5-3. HAOSMCs lacking CD9 display altered actin arrangement and a 
decrease in active RhoA and collagen gel contraction. 
(A) Ctr and CD9 shRNA cells were fixed, permeabilized and stained with alexa-fluor 594 
conjugated phalloidin and viewed using a immunofluorescent deconvolution microscope 
(scale bar, 50μm). (B) Quantification of actin filament length was performed using 
ImageJ analysis software (n=15 cells; **P<0.01). (C and D) Total and GTP-bound 
(active) RhoA was measured in whole cell lysates from Ctr and CD9 shRNA HAOSMC 
using an ELISA and the absorbance values were converted to concentration values from a 
standard curve (n=3; NS indicates no significant difference; **P<0.01). (E and F) A 
representative image of a collagen gel contraction assay taken at 6 hours and 
quantification of the percent contraction over time (n=3/time point; *P<0.05 versus CD9 
shRNA at indicated time point). 
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Activation of RhoA Restores the CD9 shRNA HAOSMC Phenotype 
 
 The observed deficiency of GTP-bound RhoA and loss of the contractile 
phenotype of CD9 shRNA HAOSMC led to the hypothesis that RhoA was responsible 
for this phenomenon. The cell permeable RhoA activator CN03 which blocks intrinsic 
GTPase activity to sustain GTP-bound RhoA in CD9 deficient HAOSMC [168] was used 
to this end. Upon restoration of GTP-bound RhoA (Figure 5-4A) and without 
significantly affecting the levels of total Rho (P=0.19; Figure 5-4B), an increase in the 
contractile capability of CD9 shRNA HAOSMC was observed (Figure 5-4C). The 
significant difference in contraction observed between the two cell groups was no longer 
obvious after treatment of CD9 shRNA cells with CN03 (Figure 5-4D). Comparison of 
the actin cytoskeleton of CN03 treated CD9 shRNA HAOSMC revealed that actin stress 
fibers were arranged more parallel to one another than the untreated cells (Figure 5-4E). 
However, the CN03 treated cells did not display the elongated stress fibers originally 
observed in the Ctr shRNA HAOSMC. These data indicate that the absence of active 
RhoA results in a lack of actin arranged in parallel, elongated stress fibers, and that active 
RhoA is necessary for HAOSMC-mediated collagen gel contraction. 
 
 
Deficiency of Active RhoA or Loss of Total RhoA Mimics the CD9 shRNA 
HAOSMC Phenotype 
 
 To further attribute RhoA activity to HAOSMC capability to contract, GTP-
bound RhoA was inhibited in Ctr shRNA HAOSMC using CT04. CT04 is a cell 
permeable C3 transferase derived from C. botulinum which works by inhibiting RhoA 
ADP-ribosylation but does not affect Rac or Cdc42 activity [169]. ELISA analysis 
confirmed that GTP-bound RhoA was significantly decreased after treatment with CT04 
without affecting total RhoA levels (Figure 5-5A and 5-5B). Contraction of CT04-treated 
Ctr shRNA cells was significantly reduced compared to the untreated cells (Figure  
5-5C). This difference was observed for the duration of the assay (Figure 5-5D). In 
addition to suppressing RhoA activity, the expression of RhoA was knocked down in Ctr 
shRNA HAOSMC using short interfering RNA (siRNA). Knockdown of RhoA was 
confirmed at both the mRNA and protein levels (Figure 5-5E and 5-5F). The absence of 
RhoA was sufficient to inhibit collagen gel contraction of Ctr HAOSMC treated with 
siRNA (Figure 5-5G and 5-5H). The RhoA siRNA treated cells were significantly less 
contractile after 1 hour and remained so after 6 hours. These data lead us to conclude that 
the absence of RhoA is responsible for the loss of contraction observed in HAOSMC 
lacking CD9. 
 
 
CD9 Contributions to Vascular Cell Biology 
 
 This study aimed to further clarify the underexplored role of tetraspanin CD9 in 
VSMC biology. The augmented expression of CD9 was investigated in the synthetic 
phenotype of HAOSMCs. It was found that downregulating the expression of CD9 
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Figure 5-4. Activation of RhoA restores the contractile capabilities of CD9 
shRNA HAOSMC and partially restores actin arrangement. 
(A and B) GTP-bound (active) and total RhoA was quantitated using whole cell lysates of 
Ctr shRNA HAOSMC or CD9 shRNA HAOSMC treated with the RhoA activator CN03 
(2.0μg/ml) for two hours (n=3; NS indicates no significant difference; **P<0.01). (C and 
D) CD9 shRNA cells were treated with CN03 (2.0μg/ml) for two hours prior to releasing 
the sides of a collagen gel contraction assay. A representative image of a collagen gel 
contraction taken at 6 hours and quantification of collagen gel contraction from 0-6h is 
shown (n=3/time point).(E) A representative Immunofluorescent stained image of f-actin 
arrangement from three independently repeated experiments in untreated Ctr shRNA and 
CD9 shRNA treated with (2.0μg/ml) for two hours (scale bar, 50μm). 
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Figure 5-5. Suppression of active RhoA or knockdown of total RhoA in 
HAOSMC mimics the phenotype of CD9 shRNA HAOSMC. 
(A and B) Quantification of the concentration of GTP-bound (active) and total RhoA in 
untreated or CT04 (2.0μg/ml for two hours) treated Ctr shRNA HAOSMC (n=3; NS 
indicates no significant difference; **P<0.01 versus untreated cells). (C and D) 
Representative image of collagen gel contraction after 6 hours and quantification of 
collagen gel contraction from 0-6 hours after treating Ctr shRNA HAOSMC with CT04 
(2.0μg/ml) for two hours prior to releasing the sides of the solidified gel (n=3/time point; 
*P<0.05, **P<0.01 versus CT04 treated cells at each time point). (E and F) 
Quantification of the concentration of GTP-bound (active) and total RhoA in scrambled 
control (Ctr) short interfering RNA (siRNA) or RhoA siRNA transfected HAOSMC 
(n=3; NS indicates no significant difference; **P<0.01 versus Ctr shRNA treatment). (G 
and H) Representative image of collagen gel contraction after 6 hours between Ctr 
siRNA and RhoA siRNA transduced HAOSMC and quantification of collagen gel 
contraction from 0-6 hours (n=3/time point; *P<0.05, **P<0.01 versus RhoA siRNA). 
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resulted in a pronounced morphologic change. The majority of cells lacking CD9 were 
significantly decreased in size and more rounded in shape.  CD9 deficient cells were also 
less proliferative at 24, 48, and 72 hours; however, the proliferation for both groups of 
cells plateaued after 48 hours. The fact that cells expressing CD9 were more proliferative 
than their CD9 shRNA counterparts was not entirely surprising because RhoA activity is 
directly linked to stimulate cell proliferation [170, 171]. Significant differences in the 
expression of commonly explored smooth muscle cell markers excepting for calponin 
were not observed. Calponin was upregulated upon knocking down CD9. Previous 
reports generally confirm a phenotypic switch to the dedifferentiated phenotype as 
indicated by a comprehensive decrease in the expression of multiple smooth muscle cell 
markers [172-174]. The morphological and proliferative data implied that the smooth 
muscle cells were in their synthetic state. However, the absence of a change in the 
expression of SM α-actin and SM22α and the increase of calponin expression challenged 
this hypothesis. 
 
 It was explored that the morphologic difference may be due to a change in the cell 
cytoarchitecture due to the absence of CD9. These observations suggest that knocking 
down CD9 disrupts the coordinated signaling between the ECM and the cells that elicits 
actin arrangement. This hypothesis is supported by the fact that while F-actin appears to 
be intact and at a similar density between the two cells types, the F-actin in CD9 shRNA 
cells lacks the parallel arrangement seen with the Ctr shRNA cells. The circular 
arrangement of F-actin in CD9 shRNA HAOSMC was most likely due to the cell’s 
inability to spatially organize signaling from the ECM due to the loss of CD9 at the cell 
surface. The observed loss of contractility was consistent with a previous report 
demonstrating a direct correlation between RhoA expression and VSMC contraction 
[175]. 
 
 The CD9 shRNA cell phenotype was then reversed upon restoration of RhoA 
activity suggesting that the loss of RhoA activity is cause for the inability for actin to 
properly arrange and the cells to contract. Interestingly, treatment of CD9 shRNA 
HAOSMC with CN03 resulted in significantly more GTP-bound RhoA compared to 
untreated Ctr shRNA cells. Despite the increased active RhoA levels in these cells, the 
plots of contraction over time between the two groups were superimposable. The amount 
of total RhoA in the Ctr and CD9 shRNA, HAOSMCs accounts for the limits of cell 
contraction. This idea is substantiated by later findings that loss of GTP-bound RhoA 
results in a drastic loss of cell contraction while loss of total RhoA results in significant 
but less pronounced contraction differences. 
 
 Rho GTPase activation is multifaceted; however, there is an abundance of 
literature that suggests that integrins [176, 177] and tetraspanins [178-180] may regulate 
RhoA activation by outside-in signaling from the ECM. The expression of tetraspanin 
CD151 was recently demonstrated to upregulate the activation of small GTPases 
including Ras, Rac, and Cdc42, but not RhoA in an adhesion-dependent manner [181]. 
The authors demonstrated that the expression of tetraspanins CD9, CD81, or CD82 was 
not able to incite a similar response for Ras, Rac, or Cdc42 activation, but did not 
measure RhoA expression or activation for these tetraspanins [181]. These experiments 
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were conducted on laminin, a well-characterized substrate for α3β1 and α6β1 integrins. 
The α3β1 and α6β1 integrins closely associate with CD151 and have been previously 
demonstrated to activate Rac without affecting Rho [182]. On the other hand, the 
fibronectin-binding integrin α5β1 selectively activates Rho [182, 183] and its expression 
is upregulated after arterial injury [184]. This laboratory has previously demonstrated that 
CD9 associates with α5β1 integrin in multiple cell lines including VSMCs [142, 143]. 
Perhaps the expression and association of CD9 and α5β1 in VSMC pathologies stabilizes 
the interaction between the integrin and ECM to augment RhoA activation. The 
importance of this interaction is highlighted by the findings that suppression of Rho 
kinase (ROCK), a direct effector of active RhoA, led to decreased neointimal formation 
in two animal models [185, 186] and prevented the formation of spontaneous 
hypertension in rats [187]. 
 
 These results suggest that CD9 does not function as an integrator linking 
lamellipodial or filopodial extensions. Although Rac activity was not measured in this 
study, the absence of lamellipodial formation may be due to the previous finding that 
CD9 expression downregulates WAVE expression, which is the downstream effector of 
active Rac and directly regulates lamellipodial formation [188]. These results substantiate 
the hypothesis that CD9 is working directly via RhoA to regulate actin rearrangement and 
cell contraction in HAOSMCs. Collectively, the previous and current findings from this 
laboratory and the report that CD151 controls the activity of Ras, Rac, and Cdc42 but not 
RhoA contribute to the premise that different tetraspanins may regulate different aspects 
of GTPase signaling. 
 
 CD9 may function in microRNA (miRNA)-based translational repression to 
regulate the contractile phenotype of VSMC. These preliminary studies have indicated no 
difference in the expression of miRNAs that play a role in suppressing the expression of 
SMC markers including miR221 and miR222 [189, 190]. Conversely, a change in 
miR145 expression which positively correlates with the contractile phenotype of VSMCs 
was not detected [190]. However, an increase in miR-1 expression upon knock down of 
CD9 expression was observed (Figure B-1). Jiang et al. demonstrated that the induction 
of miR-1 expression by myocardin resulted in a negative feedback loop and a loss of 
collagen gel contraction in HAOSMCs [191]. More interestingly, in the same study, miR-
1 expression suppressed the expression of SMC markers, specifically SM α-actin and 
SM22α [191]. The miR-1 expression induced upon knockdown of CD9 in this study may 
play a negative feedback role in the suppression of SM α-actin and SM22α which would 
otherwise be augmented. Thus, an increase in the expression of SM α-actin or SM22α 
upon knockdown of CD9 was not observed. Despite a possible block of augmented SM 
α-actin and SM22α expression, the increase in calponin expression in CD9 deficient cells 
may be enough to restore them to a contractile phenotype. Long et al. demonstrated that 
calponin overexpression alone was adequate to suppress neointimal formation in vivo 
[192]. SMC markers are used ubiquitously throughout the literature to define the 
phenotype of VSMCs; however, sole reliance on SMC markers to determine the 
phenotype in this case was not sufficient.  
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 This study adds to the understanding of how tetraspanin CD9 contributes to the 
molecular mechanisms that may control VSMC transformation of phenotype. The 
absence of CD9 alone is enough to effect major changes in the VSMC complex 
phenotype by regulating the arrangement of the actin cytoskeleton and contraction of 
HAOSMC through the activity of RhoA. Thus CD9, through signaling mediators, 
integrins, and the reciprocal coordination of the cell cytoskeleton, is added to the list of 
factors that provide flexibility for VSMC phenotypic modulation. How CD9-induced 
changes are involved in contributing to the pathophysiology of vascular injury response 
and atherosclerotic lesion development remains to be established. 
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CHAPTER 6.    INSIGHTS INTO CD9 FUNCTION FROM THESE TWO 
MODELS 
 
 
 In both of these model systems, CD9 possibly influences the resulting phenotypes 
by manipulating α5β1 integrin interaction with fibronectin. Multiple findings from this 
report support this hypothesis. First, both cell lines demonstrate cell surface expression of 
α5 and β1 integrin subunits (see Figure B-2 for HAOSMC cell surface expression). 
Second, both cell lines were subjected to fibronectin. All experiments involving HT1080 
cells took place on a full-length fibronectin substrate in the absence of serum 
(Experimental Design in Chapter 2 Materials and Methods). HAOSMC experiments were 
conducted in serum-containing media in plastic cell culture dishes. HAOSMCs were 
adherent to uncoated plastic culture dishes under these conditions 20 minutes after plating 
(personal observations). HAOSMCs in serum-containing media secrete fibronectin to aid 
in cell adherence and proliferation [193]. This occurrence involves tyrosine kinases and 
FAK signaling [194]. In fact, the functional RGDS peptide from fibronectin alone, shown 
previously by this laboratory to bind CD9 [108], can induce the synthetic phenotype of 
SMCs [195]. The absence of CD9 may slow the production of fibronectin in the CD9 
shRNA treated HAOSMC resulting in decreased proliferation observed. However, the 
secretion of fibronectin or other ECM proteins from Ctr and CD9 shRNA treated 
HAOSMC was not measured in this report and is of important and future interest. Ctr and 
CD9 shRNA HAOSMC cell viability must also be assessed. Although care was taken to 
treat and test both cell types and lysates at equal densities and concentrations 
respectively, the CD9 shRNA cells resembled an apoptotic phenotype. The CD9 shRNA 
HAOSMC response to RhoA activation (CN03) suggests that they are viable; however, 
measuring total and activated caspase-3 would be necessary to confirm equal viability 
between the two groups. 
 
 Findings from this study strongly implicate that CD9 expression induces PI3K- 
and ERK-dependent signaling pathways to elicit the observed phenotypes. Tetraspanins 
not linked to integrins have been demonstrated to signal though PKC-dependent 
pathways [161, 196]. These integrin-free tetraspanins are considered to be activated by 
forming homoclusters [196]. The results presented here, previously in this laboratory, and 
by others indicate that CD9 does not signal though PKC-dependent pathways to elicit the 
phenotypes observed herein. In this report Pro-MMP-9 production was diminished upon 
treatment with LY294002, U0126, and PD98059 (Figure B-3). Kotha et al. determined 
that CD9 induced phenotypes in a CHO cell line directly depend upon α5β1 by using an 
anti-α5β1 antibody to disrupt CD9-induced motility [142]. This CD9-dependent 
phenotype was dependent upon PI3K and Akt signaling, but not PKC or MAPK signaling 
[142]. The lack of MAPK involvement is interesting. This dissertation report proposes 
that ERK1/2 signaling is a consequence of EGFR activity. CHO cells do not 
endogenously express EGFR [111, 197, 198]. Therefore, the model system used by Kotha 
et al. focused precisely on CD9-α5β1 interaction and concluded that PKC was not 
involved in the observed phenotype. Other studies involving manipulations of pro-MMP-
9 expression similarly implicate the PI3K and ERK pathways [140, 141, 156]. PKC-
dependent activation of MMP-9 only occurs in the presence of phorbol 12-myristate 13-
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acetate stimulation [155]. These findings suggest the CD9-α5β1-FN interaction to signal 
through PI3K and the CD9-EGFR-FN interaction to signal through the MAPK/ERK 
pathway. These two pathways converge to elicit the expression of MMP-9 (Figure 6-1). 
 
 How is RhoA involved? Actin arrangement phenomena are dependent primarily 
upon the RhoA/FAK signaling pathway [199, 200]. Earlier reports from this laboratory 
[103] and others [164] implicated CD9 in FAK signaling. However, these reports are not 
entirely congruent. More interestingly, RhoA activation elicited the activation of ERK in 
a MEKK1-dependent manner [201]. EGFR activation contributed to increased cell 
motility via RhoA activation [202]. In a study observing statin-treated SMCs and MMP-9 
secretion, inhibition of RhoA or its downstream effector ROCK diminished 
experimentally-induced MMP-9 secretion [203]. Conversely, ectopic expression of 
active-RhoA induced the expression of MMP-9 in human endothelial cells [204]. The 
increased RhoA activity in this dissertation report probably resulted from the CD9-
EGFR-FN interaction. However, the CD9-α5β1-FN interaction likely plays a prominent 
role as well. Specifically integrin α5β1 expression was demonstrated to stimulate RhoA 
activity in fibroblastic and epitheloid cells [205]. The contribution of RhoA to both the 
ERK pathway and MMP-9 production were not observed in HAOSMC in this 
dissertation report. The author relentlessly tried but failed to demonstrate endogenous 
MMP-9 expression and release in HAOSMC. There are two explanations for this result. 
First, most, if not all, studies involving human or rat SMCs used cytokines or growth 
factors to stimulate MMP-9 production [206-208]. Treatment with cytokines or growth 
factors likely augments cellular signaling events well beyond the hypothetical level 
induced by manipulating CD9 expression. Furthermore, multiple other signaling 
pathways are induced by these treatments making it impossible to attribute downstream 
findings to CD9 expression. Second, the reported activation of EGFR by the integrin-FN 
association is between 9 and 22 times less than activation by the native ligand EGF [209]. 
This explains why, if EGFR has a role in SMC MMP-9 release, MMP-9 release is not 
observed. However, this should not complicate the HT1080-MMP-9 paradigm because 
HT1080s endogenously secrete copious amounts of MMP-9 [128, 210]. Therefore, even a 
slight manipulation of signaling may augment MMP-9 expression two to four fold.   
 
 The findings presented here demonstrate potentially overlapping CD9 signaling 
mechanisms in two model systems. The idea that cellular signaling is a linear event is 
sophomoric. CD9 likely influences the downstream events of multiple associated proteins 
concurrently resulting in complex cellular phenotypes. The single most alluring finding is 
that CD9 has an effect on these phenotypes! This highlights the necessity for cell surface 
organization by tetraspanins to influence cellular phenotype. Therefore, in consideration 
of basketball being the author’s preferred sport, CD9 is likened to the sixth man. The 
game may still be played in its absence, but its presence significantly influences the 
outcome. 
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Figure 6-1. The proposed CD9 signaling pathway derived from both model 
systems. 
Black arrows indicate proposed signaling from the CD9-α5β1-FN triad and dark green 
arrows indicate signaling from the CD9-EGFR-FN interaction observed in HT1080 cells. 
Purple arrows indicate signaling observed in HAOSMCs. The red arrow indicates where 
these two pathways possibly converge in eliciting MMP-9 expression. 
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CHAPTER 7.    FUTURE DIRECTIONS 
 
 
 The HT1080 cell model system used in this report was integral in elucidating the 
specific contributions of CD9 to cellular invasion. Yet, the clinical relevance of this 
model is severely lacking. There are only 500 new cases of human fibrosarcoma reported 
each year in the United States and the post-treatment survival averages are 90% 
(http://www.healthline.com/ galecontent/fibrosarcoma/ accessed November 20, 2013). 
Veterinarians may benefit from these findings as the incidence of feline fibrosarcoma is 
rather high [211]. However, the expression of CD9 in feline fibrosarcomas is unknown 
and may be endogenously low. In either case, the manipulation of CD9 expression would 
potentially result in unwanted outcomes. 
 
 The conclusion that CD9 promotes the invasive phenotype of cancer cells is more 
usefully applied to a human non-small cell lung cancer (NSCLC) cell line. NSCLCs 
make up approximately 90% of all lung cancers (http://www.healthline.com/health/lung-
cancer-non-small-cell/ accessed November 20, 2013). The occurrence of this type of lung 
cancer is mostly independent of cigarette smoking (http://www.cancer.org/cancer/ 
lungcancer-non-smallcell/ accessed November 20, 2013). NSCLC demonstrate all of the 
necessary characteristics to warrant studying the effect of CD9 expression in these cells. 
Human NSCLC biopsies demonstrated MMP-9 and membranous EGFR coexpression 
that positively correlated with a poor prognosis [114]. As previously mentioned (Chapter 
4), the level of CD9 expression in NSCLC cells is similar to that achieved in HT1080 
cells [70]. Screening for CD9 expression in conjunction with MMP-9 and EGFR in 
NSCLC biopsies may significantly improve the prognostic value. It has already been 
concluded that CD9 expression is a poor prognostic indicator in NSCLC malignancies 
[212, 213]. Manipulations of CD9 in NSCLC and resultant phenotypes have yet to be 
discovered. 
 
 The influence of CD9 on the contractile phenotype of HAOSMCs is more 
perplexing. RhoA and SMC contraction is an extremely well-studied event. Focusing 
efforts on the mechanism of CD9 regulation of RhoA activity would be more beneficial. 
This phenomenon most likely results from the association of CD9 with α5β1 integrin. 
The lack of a completely transparent phenotype as measured by SMC markers is 
unfortunate. Using miR expression to explain these results is preliminary and requires 
much more analysis. In spite of this, SMC marker expression is not always an indicator 
of the contractile capabilities of SMC cells (personal communication with Brian 
Wamhoff, Ph.D. on September 6, 2013). Overall, future studies involving CD9 will 
always require careful consideration of the cell-specific phenotypes elicited by the CD9-
α5β1-FN interaction.  
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APPENDIX A. QRT-PCR PRIMERS 
 
 
Table A-1. List of primers and probes used for tetraspanin and integrin qRT-
PCR analysis. 
 
Gene  Direction  Primers  Taqman probe 
CD9 EC1 Forward GAGGCACCAAGTGCATCAA 56 Reverse AGCCATAGTCCAATGGCAAG 
CD9 EC2 Forward GGCGTGGAACAGTTTATCTCA 43 Reverse GATGGCATCAGGACAGGACT 
CD63 Forward TGAAATGTGTGAAGTTCTTGCTC 18 Reverse CAATCAGTCCCACTGCACA 
CD81 Forward TCGTCTTCAATTTCGTCTTCTG 19 Reverse CTCCCAGCTCCAGATACAGG 
CD151 Forward GGAGCTTCTGTCCACCTGTC 82 Reverse TCGTTGAACTCACCCATCCT 
α2 Forward TCGTGCACAGTTTTGAAGATG 7 Reverse TGGAACACTTCCTGTTGTTACC 
α4 Forward GATGAAAATGAGCCTGAAACG 22 Reverse GCCATACTATTGCCAGTGTTGA 
α5 Forward ACCCTGCCGCTCAGATTT 18 Reverse AAAACCACACGGCCAGTC 
α6 Forward TGGCCTCTTCATTTGGCTAT 77 Reverse AAAATACTGTGGGGCTCCAAT 
β1 Forward TTCGATGCCATCATGCAA 19 Reverse ACACCAGCAGCCGTGTAAC 
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Table A-2. List of primers and probes used for MMP and TIMP qRT-PCR 
analysis. 
 
Gene 
 
Direction 
 
Primers 
 
Taqman 
Probe 
MMP-1 Forward GCTAACCTTTGATGCTATAACTACGA 7 Reverse TTTGTGCGCATGTAGAATCTG 
MMP-2 Forward ATAACCTGGATGCCGTCGT 70 Reverse AGGCACCCTTGAAGAAGTAGC 
MMP-3 Forward GCAAGGACCTCGTTTTCATT 6 Reverse CTCTTGGGTATCCAGCTCGT 
MMP-7 Forward TGGACGGATGGTAGCAGTCT 6 Reverse TCTCCATTTCCATAGGTTGGAT 
MMP-8 Forward GGGAACGCACTAACTTGACC 30 Reverse TTCAAAGGCATCCTTGATAGC 
MMP-9 Forward GAACCAATCTCACCGACAGG 6 Reverse GCCACCCGAGTGTAACCATA 
MMP-14 Forward CTGTCAGGAATGAGGATCTGAA 37 Reverse AGGGGTCACTGGAATGCTC 
MMP-16 Forward AGGGCATCCAGAAGATATATGG 39 Reverse GGCACTGTCGGTAGAGGTCTT 
TIMP1 Forward GGGCTTCACCAAGACCTACA 76 Reverse TGCAGGGGATGGATAAACAG 
TIMP2 Forward GAAGAGCTTGAACCAACAGGT 43 Reverse CGGGGAGGAGATGTAGCAC 
TIMP3 Forward TGCAACTCCGACATCGTG 60 Reverse AAGGGCCCCTCCTTTACC 
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Table A-3. List of primers and probes used for EGFR and HAOSMC qRT-PCR 
analysis. 
 
Gene 
 
Direction 
 
Primers 
 
Taqman 
Probe 
EGFR Forward CATGTCGATGGACTTCCAGA 44 Reverse GGGACAGCTTGGATCACACT 
SM α-
actin 
Forward CTGTTCCAGCCATCCTTCAT 58 Reverse TCATGATGCTGTTGTAGGTGGT 
SM22α Forward CAGTGTGGCCCTGATGTG 41 Reverse CACCAGCTTGCTCAGAATCA 
Calponin Forward CCAACCATACACAGGTGCAG 79 Reverse TCACCTTGTTTCCTTTCGTCTT 
RhoA Forward GGGAGCTAGCCAAGATGAAG 13 Reverse GTACCCAAAAGCGCCAATC 
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APPENDIX B. SUPPLEMENTARY FIGURES FROM CHAPTERS 5 AND 6 
 
 
 
 
 
Figure B-1. Expression of microRNAs between Ctr and CD9 shRNA HAOSMC. 
MicroRNA (miRNA) was harvested from Ctr and CD9 shRNA HAOSMC and screened 
for four miRNAs of interest. 
 
 
 
 
 
Figure B-2. The expression of integrin α5 and β1 subunits on the cell surface of 
naïve HAOSMC. 
The cell surface expression of α5 and β1 integrin subunits was measured on non-
permeabilized, naïve HAOSMC. The shaded histograms in each panel represent non-
specific IgG antibody binding. The unshaded histograms indicate the integrin labeled in 
each panel. 
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Figure B-3. Inhibition of pro-MMP-9 gelatinolytic activity by LY294002, U0126, 
and PD98059. 
Mock and CD9 HT1080 cells were plated on fibronectin in the presence of equal volumes 
of DMSO or the above inhibitors at a final concentration of 5μM. After 24 hours, the 
media was harvested, cleared, and subjected to gelatin zymographic analysis. 
Densitiometry was performed using ImageJ software and band density values were 
normalized to Mock+DMSO (n=3). 
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